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Computational Analysis of Biomolecular Data for Medical Applications from Bulk to Single-cell 
Kaiyi Zhu 
 
 High-throughput technologies have continuously driven the generation of different 
biomolecular data, including the genomics, epigenomics, transcriptomics, and other omics data in 
the last two decades. The developments and advances have revolutionized medical research. In 
this dissertation, a collection of computational analyses and tools, based on different types of 
biomolecular data with particular applications on human diseases are presented including 1) a 
cascade ensemble model based on the Dirichlet process mixture model for reconstructing tumor 
subclonality from tumor DNA sequencing data; 2) a meta-analysis of gene expression and DNA 
methylation data from prefrontal cortex samples of patients with neuropsychiatric disorders 
indicating a stress-related epigenetic mechanism; 3) 2DImpute, an imputation algorithm that is 
designed to alleviate the sparsity problem in single-cell RNA-sequencing data; and 4) a pan-cancer 
transformation from adipose-derived stromal cells to metastasis-associated fibroblasts revealed by 
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Chapter 1: Introduction 
 
1.1 Background 
Complex diseases, such as cancer, psychiatric disorders, diabetes, and cardiovascular disease, have 
high prevalence in the general population and are a result of sophisticated interactions involving 
many genes, frequently coupled with environmental influences. To understand the underlying 
biological processes systematically and holistically, one must interpret the biomolecular intricacy 
and variations at multiple levels, such as genome, epigenome, transcriptome, proteome, 
metabolome, and microbiome [1], [2]. The advent of high-throughput assessments including 
array-based [3] and the subsequent next-generation sequencing (NGS) technologies [4] has 
revolutionized medical research [5] by allowing global, rather than local, measurement of these 
biomolecules. In this thesis, I analyze the biomolecular data of the first three levels: genome, 
epigenome, and transcriptome.  
At the genome (DNA) level, alterations in genes are analyzed, such as single-nucleotide 
polymorphisms (SNPs), copy number alterations (CNAs), and insertions-deletions (indels). DNA 
microarrays [6], and NGS technologies which include whole-genome sequencing (WGS) [7], 
whole-exome sequencing (WES) [8] and targeted sequencing (TS) [9], have been developed to 
study these alterations. WGS enables the characterization of alterations in both the coding and 
non-coding regions of the genome, whereas WES and TS are more cost-effective alternatives that 
are focused on specific regions of the genome.  
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The epigenome encompasses all the chemical modifications to DNA and histone proteins 
that regulate the expression of genes in the genome. Epigenetic changes can switch genes on or 
off and determine which proteins are transcribed not by changing the DNA sequence, but by 
modifying DNA methylation and remodeling the chromatin structure [10]. Disrupting any 
epigenetic systems can cause abnormal activation or silencing of genes. Increasing evidence has 
shown that the environmental factors are able to alter gene expression and change phenotype, in 
part by modifying the epigenome, and potentially changing disease susceptibility when the 
adaptations occur at crucial stages [11]. DNA methylation is one of the most extensively 
investigated epigenetic changes, taking place at the carbon-5 position of cytosine residues in CpG 
dinucleotides. Methylation status can be quantified by both microarray [12] and sequencing 
technologies [13].   
The transcriptome is the collection of all RNA transcripts in cells or tissues. 
Transcriptomes can be studied using hybridization-based or sequence-based approaches. 
Researchers have widely used microarrays following their invention because they provide an 
affordable means of simultaneously measuring the expression level of thousands of genes at once 
[14]. RNA sequencing (RNA-seq) has replaced microarrays as an indispensable tool for 
transcriptome-wide analysis since the late 2000s because it provides a far more precise 
measurement of levels of transcripts and their isoforms [15].  
However, bulk RNA-seq and microarrays reflect the average expression level for each gene 
across a large population of input cells, which is insufficient to provide insights when studying 
heterogeneous systems. Therefore, the development of NGS technologies in recent years 
increasingly focuses on the characterization of individual cells. These single-cell analyses allow 
researchers to study longstanding questions in biology and medicine in which cell-specific changes 
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are important, unattainable when using conventional bulk population profiling [16]. Single-cell 
RNA sequencing (scRNA-seq), a great advancement in the past decade, provides unprecedented 
opportunities to measure the gene expression at the single-cell level [17]. A more precise 
understanding of the transcriptome in individual cells will become possible, which is essential to 
elucidate their role in cellular functions, revealing complex and rare cell populations, and tracking 
the trajectories of distinct cell lineages [18]. Despite substantial advances, a number of new and 
unique challenges in the emerging field of single-cell data analysis have appeared and remain to 
be resolved [19], [20].   
 
1.2 Thesis overview 
This thesis summarizes several projects conducted on diverse high-throughput biomolecular data 
and their applications to human diseases. For data types, Chapters 2 and 3 present the research 
based on traditional bulk data (including DNA sequencing, gene expression, and DNA 
methylation), whereas Chapters 4 and 5 focus on analyzing scRNA-seq data. For result types, 
Chapters 2 and 4 develop models and algorithms for specific problems, whereas Chapters 3 and 5 
include computational analyses in the scenarios of different diseases. Specifically, Chapter 2 
presents a cascade ensemble model based on the Dirichlet process mixture model for tumor 
subclonal reconstruction. Given the DNA sequencing data of a tumor sample, this model infers the 
number of subclones of cancerous cells, characterizing them in terms of mutation assignments, 
cellular proportions, and their evolutionary relationships.  
 Chapter 3 describes a meta-analysis of expression and methylation signatures in different 
neuropsychiatric disorders. We gathered a data cohort of postmortem prefrontal cortex samples 
from individuals with six different neuropsychiatric disorders and healthy controls, and then 
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applied an unsupervised computational approach identifying several consensus co-expression and 
co-methylation signatures. By investigating these consensus signatures, we identified a pair of 
strongly interrelated co-expression and co-methylation (E-M) signatures showing consistent and 
significant disease association in multiple types of disorders.  
In Chapter 4, we developed an imputation algorithm to alleviate the sparsity problem in 
scRNA-seq data by predicting and correcting false zeros (also known as dropouts). The dropout 
effect is a unique problem manifesting in scRNA-seq data, posing challenges for downstream 
analyses. By leveraging the interrelationships between genes and cells in the expression matrix, 
2DImpute is able to accurately predict and impute false zeros while preventing excessive 
correction. 
Chapter 5 shows a follow-up study of our previous work in 2010 [21] thanks to the 
availability of enormous single-cell expression data of human cancers. During the last ten years, 
many research results have referenced a particular type of cancer-associated fibroblasts associated 
with invasiveness, metastasis and resistance to therapy, present in nearly identical form in many 
individual types of solid cancer. The expression of several genes, prominent among them 
COL11A1, THBS2, and INHBA characterize these fibroblasts. Identifying the origin of this 
universal metastasis-associated fibroblastic cell population and the underlying biological 
mechanisms responsible for their creation may help in identifying drug targets for pan-cancer 
metastasis-inhibiting therapeutics. This information, however, remains elusive. We have 
performed an extensive computational analysis of single-cell gene expression data from many 
cancer types, concluding that a cancer-associated transformation of naturally occurring normal 
adipose-derived stromal cells produce these COL11A1-expressing fibroblasts.  




Chapter 2: Tumor Subclonal Reconstruction from DNA Sequencing 
Data using a Cascade Ensemble Model 
 
2.1 Introduction 
Cancer is a dynamic disease. Most tumors arise from a single ancestral cell whose genome acquires 
one or more somatic driver mutations [22], [23] to gain itself a fitness advantage over its 
neighboring cells by manifesting the hallmark characteristics of cancers [24]. This ancestral cell 
and its descendants proliferate, ultimately giving rise to all cancerous cells in a tumor. Over time, 
these cells accumulate mutations, some leading to further fitness advantages. Eventually, local 
clonal expansions can create unique subpopulations of tumor cells sharing subsets of mutations, 
also called “subclones”. During the course of disease, cancers generally become more 
heterogeneous. As a result, a bulk solid tumor could include a diverse collections of cancer cell 
subclones that independently evolve in different regions, harboring distinctive genetic 
characteristics. Studies have shown that intratumoral heterogeneity closely relates to cancer 
progression and underlies resistance to therapy and recurrences [25], [26]. Higher levels of tumor 
heterogeneity can lead to a reduced effectiveness in cancer therapies. Therefore, understanding the 
heterogeneity of tumors is critical for us to learn more about the disease, and gain insights by 
linking to clinical phenotypes and therapy response.  
 DNA sequencing has enabled patients’ tumors to be analyzed in unprecedented detail [27]. 
It allows quantification of the frequency of specific mutations based on measurements of the 
fraction of mutant sequencing reads, the copy number state of the locus, and the tumor purity [28], 
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[29]. By aggregating these noisy frequency measures across mutations, a tumor sample’s subclonal 
architecture can be reconstructed from bulk sequencing data [29], [30]. Although many subclonal 
reconstruction methods have been developed in recent years [31]–[34], no benchmarking of the 
accuracy of these approaches has emerged. Therefore, to identify the most appropriate methods to 
accurately reconstruct the tumor subclonal architecture based on unbiased rigorous benchmarking, 
a crowd-sourced challenge,  ICGC-TCGA DREAM Somatic Mutation Calling Tumor 
Heterogeneity (SMC-Het) Challenge [35], was launched. We participated in this Challenge and 
developed a cascade ensemble model based on the Dirichlet process mixture model for inferring 
tumor subclones.  
 
2.2 Materials and Methods 
2.2.1 Input data 
The Challenge organizers simulated realistic tumor genomes by using the BAMSurgeon tool [36] 
with additional features [35] to provide gold-standard truth for subclonal reconstruction. Two input 
data files were provided for each tumor sample: One was somatic single nucleotide variants (SNVs) 
called by MuTect [37] in variant call format (VCF), and the other was the subclonal copy number 
aberrations (CNAs) identified using Battenberg [30]. 
 
2.2.2 Sub-challenge questions 
The Challenge structured the problem into three sub-challenges. Sub-challenge 1A–1C 
(“subclonal architecture challenges”) evaluated properties of the subclonal reconstruction without 
considering the assignment of individual SNVs to subclones. Sub-challenge 2A and 2B 
(“clustering challenges”) evaluated the assignments of individual SNVs to subclones. 
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Sub-challenge 3A and 3B (“ancestry challenges”) evaluated the ancestral relationships of 
individual SNVs. Challenge description follow.  
Sub-challenge 1: Subclonal architecture.  
• 1A: cellularity. Predict the proportion of cells in the sample that are cancerous (that is, the 
tumor purity of the sample). The output is a real number c with 0 ≤ 𝑐 ≤ 1. 
• 1B: subclone count. Predict the number of subclones present in the sample. It is assumed 
that each sample has at least one (that is, clonal) subclone. The output is a positive integer 
𝜅 and 𝜅 ≥ 1. 
• 1C: subclonal architecture. Predict (1) the proportion of cells in the tumor sample in each 
of the subclones and (2) the number of SNVs associated with each subclone.  
Sub-challenge 2: Clustering.  
• 2A: single best hard assignment. Predict the assignment of each mutation to each 
subclone. The output 𝜏 is a vector of n positive integers, where n is the number of SNVs, 
in which each element 𝜏!  represents the index of the subclone to which mutation i is 
assigned. Thus, 1 ≤ 𝜏! ≤ 𝜅. 
• 2B: probabilistic co-clustering. Predict which pairs of mutations are in the same cluster. 
The predicted co-clustering matrix (CCM), which is an 𝑛 × 𝑛 matrix of real numbers, 
where 𝐶𝐶𝑀!" is the probability that mutation i is in the same subclone as mutation j, and 
0 ≤ 𝐶𝐶𝑀!" ≤ 1. Every mutation is assigned to the same subclone as itself, so it is required 




Sub-challenge 3: Ancestry.  
• 3A: single best ancestry. Predict the ancestral relationships among the predicted 
subclones. The output is a vector p of 𝜅 positive integers. Each element, for example, 𝑝# 
is the index of the predicted parental subclone for subclone k where 𝑝# = 0 indicates that 
subclone k has no parent, that is, it descends from the normal lineage. Thus, 𝑝# ≠ 𝑘 and 
0 ≤ 𝑝# ≤ 𝜅. 
• 3B: probabilistic ancestor-descendant matrix (ADM). Predict the ancestral 
relationships among pairs of SNVs. The predicted ADM, which is an 𝑛 × 𝑛 matrix where 
𝐴𝐷𝑀!" is the probability that mutation i is assigned to a subclone that is ancestral to the 
subclone that mutation j is assigned to, and 0 ≤ 𝐴𝐷𝑀!" ≤ 1. 
 
2.2.4 Scoring metrics  
To quantify the accuracy of predicted results for these sub-challenges, the SMC-Het Challenge 
organizers designed several associated scoring metrics [35], all bound between zero (very poor 
performance) and one (perfect performance). 
• Sub-challenge 1A: 1 − |𝜌 − 𝑐|, where 𝜌 is the true cellularity, 𝑐 is the inferred cellularity. 
Note that it’s required that 0 ≤ 𝜌 ≤ 1 and 0 ≤ 𝑐 ≤ 1. 
• Sub-challenge 1B: (𝐿 + 1 − 𝑑) (𝐿 + 1)⁄ , where 𝐿 ≥ 1 is the true number of subclones, 
and 𝑑 = min(|𝜅 − 𝐿|, 𝐿 + 1) with 𝜅 representing the predicted number of subclones. We 
do not allow 𝑑 to be higher than 𝐿 + 1 so that the score is always ≥ 0. 
• Sub-challenge 1C: 1 −	EMD, where EMD is the exact (normalized) earth-mover distance 
(EMD) between the true and predicted subclonal architectures. The detailed procedure for 
deriving the EMD is described in [35].   
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• Sub-challenge 2: Sub-challenges 2A and 2B use the same scoring metric, which is the 
mean of two different correlation measures between the predicted co-clustering matrix 
(CCMPr) and the true co-clustering matrix (CCMTr); the area under the precision-recall 
(AUPR) curve and the average Jensen-Shannon divergence (AJSD) of the co-assignment 
probabilities. Each correlation measure is normalized by subtracting a constant value and 
linearly scaling to be between 0 and 1. This normalization is computed so that 1 
corresponds to a ‘perfect score’ and 0 corresponds to the smaller of the scores achieved by 
two ‘bad scenarios’: CCMPr = Inxn or CCMPr = 1nxn. If a method achieves a score < 0 after 
normalization, then the score is set to zero. The overall Sub-challenge 2 score is calculated 
as the mean of the two individual normalized correlation measures.   
• Sub-challenge 3: Pearson correlation coefficient (PCC) between the true and predicted 
version of two rectangular matrices derived from ADM and CCM and their cousin matrix 
(see detailed description in [35]). The PCC between two matrices C and K is defined as: 
PCC = Cov(C, K) 𝜎$𝜎%⁄ , where Cov(C, K) is the covariance of the vectorized versions of 
C and K, 𝜎$ (𝜎%) is the standard deviation of vectorized C (K). 
 
2.3 Results 
2.3.1 Cascade ensemble model  
Model Overview. As shown in the block diagram (Figure 2.1), this model consists of four 
connected modules named Module 1 (M1) to Module 4 (M4). The input includes the given somatic 
SNV callings and subclonal CNA callings for the tumor sample (Materials and Methods). The 
output answers each of the three sub-challenges (Materials and Methods). The three blue blocks 




Figure 2.1 Schematic diagram of the cascade ensemble model. The four orange squares denote 
the four connected modules in this model (M1, M2, M3, and M4). The green parallelograms 
represent the inputs and outputs. The three blue blocks are functional processes which were 
particularly designed for different tasks. 
 
 
Module 1 was designed to derive an initial estimate of cellularity from the phased genotype 
information provided in Battenberg CNA input data, based on the allele-specific copy number 
analysis of tumors equation [38]: 
𝐵𝐴𝐹 =
𝑐 × (𝑓& × 𝑛𝑀𝑎𝑗& + 𝑓' × 𝑛𝑀𝑎𝑗') + (1 − 𝑐) × 1
𝑐 × [𝑓& × (𝑛𝑀𝑎𝑗& + 𝑛𝑀𝑖𝑛&) + 𝑓' × (𝑛𝑀𝑎𝑗' + 𝑛𝑀𝑖𝑛')] + (1 − 𝑐) × 2
 
where 𝐵𝐴𝐹 is the B allele frequency, 𝑛𝑀𝑎𝑗& and 𝑛𝑀𝑖𝑛& (𝑛𝑀𝑎𝑗'	and 𝑛𝑀𝑖𝑛') represent major and 
minor copy number of state 1 (or state 2), respectively, 𝑓&(or 𝑓') is the fraction of tumor cells 
carrying state 1 (or state 2), and all these values are available in the Battenberg file; c is the 
cellularity to estimate. Using this equation, we derived an initial estimate of cellularity, which is 
shown as 𝑐& in Figure 2.1. This value was used in the following steps in order to derive a more 




Module 2 and Module 3 are the key steps in the model for subclonal reconstruction, based on a 
truncated Dirichlet process mixture model implemented by the blocked Gibbs sampler [39], [40].  
 For a set of observed somatic mutations, we are given the total read-depth across the base 
and the number of those reads reporting the variant allele for each mutation. The number of variant 
reads can be seen as the number of successes of N independent coin tosses, where N is the total 
read depth. The number of successes (variant reads) can therefore be modeled through a binomial 
distribution  
𝑦! 	~	𝐵𝑖𝑛(𝑁! , 𝑝!) 
where 𝑦!  is the number of reads reporting the variant at location i, from the total reads 𝑁!  at 
location i, and 𝑝! the probability of observing a mutant read. Both 𝑦! and 𝑁! are observed in the 
input SNV data. 𝑝! can be considered the product of two factors [29]:  
𝑝! = 𝜁!𝜋! 
where 𝜁! is the expected fraction of reads that would report a mutation present in 100% of tumor 
cells at that locus, and 𝜋! is the true fraction of tumor cells carrying the mutation. 
Dirichlet process mixture model 
Here, 𝜋! ∈ (0, 1), the fraction of tumor cells carrying the ith mutation is the key estimate in the 
tumor subclonal reconstruction. We, following many previous methods [30]–[32], used a Dirichlet 
process (DP) to model subclonal fractions as  
𝐺	~	𝐷𝑃(𝛼, 𝐻)	
𝜋! 	~	𝐺 
where 𝐷𝑃(𝛼,𝐻) is a Dirichlet process parameterized by a base distribution H and a positive 
scaling parameter 𝛼. The DP is a measure on measures. The stick-breaking process is an explicit 




𝐺 = ∑ 𝜔(𝛿)!
*
(+& , with 𝜋(	~	𝐻, 
where 𝛿) is a point mass at 𝜋 and 𝜔( is the weight of the mutation cluster h (that is, effectively 
the proportion of all somatic mutations specific to that cluster)  
𝜔( = 𝑉(∏ (1 − 𝑉,),-( , with 𝑉(	~	𝐵𝑒𝑡𝑎(1, 𝛼) and 𝜔& = 𝑉&. 
The mixing proportions 𝜔( are given by successively breaking a unit length “stick” into an infinite 
number of pieces. The 𝑉( represents the size of each successive piece, proportional to the rest of 
the stick, and it is given by an independent draw from a 𝐵𝑒𝑡𝑎(1, 𝛼) distribution.  
 In the Dirichlet process mixture model [42], the DP is used as a nonparametric prior in a 
Bayesian specification. By treating 𝜋! as the parameter of the distribution of the ith observation, 
data generated from this model can be partitioned according to the distinct values of the parameter. 
Therefore, SNVs with the same 𝜋! inferred by the model will be assigned to the same subclone. 
Taking this view, the DP mixture model can be interpreted as a flexible mixture model in which 
the number of components is random and unbounded and grows as new data are observed [40]. 
 To compute the posterior distribution under a DP mixture prior, approximate inference 
methods are required and Monte Carlo Markov chain (MCMC) sampling provides one class of 
approximations. We applied the blocked Gibbs sampling algorithm [39], [43], proposed to avoid 
some limitations of the standard version to speed up the learning process. The blocked Gibbs 
sampler requires a truncated DP in which 𝑉%.& is set to one for some fixed K. This yields 𝜔( = 0 
for ℎ ≥ 𝐾. For this model, we set K equal to 10, as assumed in the Challenge that the number of 
subclones does not exceed 10. For prior distributions, we let 𝐻	~	𝑈𝑛𝑖𝑓(0, 1)  and 




Incorporating CNA information 
𝜁! is the proportion of variant reads one expects to see if the mutation i is fully clonal, so it can be 
calculated from the tumor purity and the copy number state of the locus. Suppose the proportion 
of cancerous cells in a tumor sample is c, the total copy number of the chromosome segment of 
this region is 𝑛/0/,/,!, and the SNV is carried by 𝑛234,/,! copies. Then 𝜁! can be expressed as  
𝜁! =
𝑛234,/,! × 𝑐
𝑛/0/,/,! × 𝑐 + 𝑛/0/,5,! × (1 − 𝑐)
 
where 𝑛/0/,5,! denotes the total number of chromosome copies in normal cells at locus i, which is 
equal to two where it becomes one if it is in a male sex chromosome. We used the CNA input data 
to map each mutation to corresponding CNA region based on chromosomal positions and 
calculated the 𝑛/0/,/,! from the inferred copy number states (that is, adding the major and minor 
allele copy numbers). 𝑛234,/,!  has several possibilities depending on whether the SNV occurs 
before or after the CNA in the same region [44]. In this model, we assume a simple situation in 
which each SNV is heterozygous and 𝑛234,/,! = 1. 
Nevertheless, to make the inference more accurate, rather than perform a single pass to the 
DP mixture model as described above, we designed two sequential passes with different inputs, 
that is, Module 2 and Module 3 respectively (Figure 2.1). We first chose to perform the 
decomposition on a selected subset of SNVs for which the total copy number exactly equals one, 
such as those somatic mutations on sex chromosomes for males and those on autosomes but with 
copy number deletions. These loci are either all variant alleles or all reference alleles. Therefore, 
the expected variant allele frequencies (𝜁! ) for these mutation loci are deterministic, and no 
arbitrary assumptions are needed. Module 2 takes as input the selected mutations and the initial 
estimate of tumor purity (𝑐&) generated by Module 1, and then outputs the decomposition result, 
including the updated estimate of tumor purity (𝑐') and the number of subclones (𝑘').  
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A decision block between Module 2 and Module 3 determines if the subclone count derived 
from Module 2 (𝑘') is equal to 1 or not. If it is true, we will claim that there is only one tumor 
subclone existing in the sample and then all other questions of the challenge can be answered as 
well. This design feature can save us a great deal of computational time for cases where tumors 
have only one subclone while containing a considerable number of somatic mutations to analyze 
(e.g. Tumour 6; Figure 2.2). Otherwise (in cases where 𝑘' > 1), indicating the tumor composition 
is more complex, we will then continue with Module 3 for a second pass by using the updated 
inputs and parameter settings (Figure 2.1).  
 
Filtering out false positive mutation callings 
Following Module 2, we then use all available SNVs as input to Module 3. However, by analyzing 
the training data, we found that there is a substantial proportion of mutations being actually false 
positive (FP) callings (Figure 2.2), which are known to be introduced by independent mutation 
calling tools [45]. Thus, we designed several filtering criteria by making use of the information 
available in the input MuTect VCF file:  
i. We exclude mutations that exist in single nucleotide polymorphism database (dbSNP). 
ii. We assume that the matched normal genome for a true SNV would be variant-free; in other 
words, the variant allele count of the matched normal sample equals zero. 
iii. We require the average base quality (BQ) to be between 32 and 39 because we found much 




Figure 2.2 Histograms of training samples showing subclonal mutation distributions. The 
information on false positives and clustering labels comes from the provided ground truth. VAF 
































































































































Heuristic phylogenetic tree construction 
Module 4. So far, we describing having obtained answers for the first two sub-challenges. 
Sub-challenge 3 was designed to identify the evolutionary relationship between the subclones. We 
obtained the flat clustering results from the previous three modules. In the last module, Module 4, 
we developed a heuristic tree building method to predict the subclone phylogeny, based on several 
assumptions. First is a most common and powerful assumption called the infinite site assumption 
[46]–[48]. It assumes that each simple somatic mutation occurs only once in the evolutionary 
history of the tumor. It implies that each subclone has all the somatic mutations that its ancestors 
had and each subclonal lineage corresponds to a subtree in the phylogeny. The second is a 
parsimony assumption [49], [50], that results in selecting the phylogeny that maximizes the 
number of vestigial clusters. For implementation, we minimize the proportion differences between 
the subclone and its children. Moreover, we assume that each subclone has no more than two 
children.  
This method is very straightforward and proves to be effective and very fast. Specifically, 
given that we’ve already had the decomposition results including the cancer cell fraction of each 
subclone (CCF; that is, the fraction of cancer cells carrying the mutations in this subclone), we 
first sort all the inferred subclones in terms of their CCFs in decreasing order. Then, we select the 
subclone with the largest CCF (subclone 1) as the root of the phylogenetic tree, and the one with 
the second largest CCF (subclone 2) as its child node. Next, we assign the third largest subclone 
(subclone 3) by following the principle of the parsimony assumption. In other words, if its CCF 
does not exceed the difference between the CCFs of the first two subclones, we can safely put it 
under the root as the second child; otherwise, we place it as the child of subclone 2 rather than the 
sibling. For the remaining subclones, we apply the rules similarly until the constructed 
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phylogenetic tree involves all the subclones. Figure 2.3 is a simple example for illustrating the 
tree constructing process. We have four subclones inferred from previous steps and we sorted them 
in terms of their CCFs. We placed the two largest subclones as the root and its first child, 
respectively. We then assigned the third subclone as the second child of the root because its CCF 
was smaller than the CCF difference of the first two subclones. As for the last subclone, due to the 
assumption that each node has no more than two children, it can only be assigned as the child of 
the second or the third subclone. Based on the parsimony assumption, we hoped to minimize the 
CCF differences between subclones and their children, so we chose to assign the fourth subclone 
to be the child of the third one due to the smaller difference. 
 
Figure 2.3 An example of building a phylogenetic tree from inferred subclones. Each circle 
represents a subclone with the CCF shown as the number in the circle.   
 
Code availability 





2.3.2 Benchmarking  
Using the quantitative metrics for scoring different sub-challenge questions (Materials and 
Methods), we compared the proposed model with two benchmark methods provided in the 
Challenge, DPClust [30] and PhyloWGS [44], using the training datasets (Table 2.1). The 
proposed model outperformed the benchmark models in all sub-challenges, and performed fairly 
well in Sub-challenges 1 and 3 while slightly worse in the Sub-challenge 2. It suggested that the 
methodology has more room for improvement regarding accurately assigning each individual SNV 
into each subclone. The leaderboards, including scores and rankings using test datasets, can be 
found on the SMC-Het Challenge website [51].   
 
Table 2.1 Median scores across all training samples for individual sub-challenges measuring 
by the scoring framework. Scores for “Benchmark” are the higher ones achieved by DPClust or 
PhyloWGS. 
Sub-challenges 1A 1B 1C 2A 2B 3A 3B 
Proposed 0.99 1.00 0.97 0.65 0.74 0.88 0.89 




To conclude, we developed a cascade ensemble model based on the Dirichlet process mixture 
model to characterize intra-tumor heterogeneity from various aspects. The model has several 
advantages. First, the cascade ensemble architecture provides flexibility for us to customize the 
model for different application scenarios in practice. For example, if SNVs are called by different 
mutation calling tools, rather than MuTect [37] which was used in the Challenge, the only part of 
the model that needs modification would be the block of detecting false positive mutation callings; 
or if an accurate estimate of tumor purity is already available at the very beginning, we can simply 
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skip Module 1 in the model, which aimed to derive a fair, initial estimate. Second, the core 
technique we employed in this model for inferring tumor subclones was a modified truncated DP 
mixture model, which features the automatic generation of the number of components. Moreover, 
during the subclonal reconstruction process, we considered the effects from the CNAs and the false 
positive mutation callings, and accordingly made correction to improve the accuracy of the 
prediction.  
Nevertheless, this model has some caveats and limitations, as does the Challenge. First, we 
only used the DNA sequencing data from one single spatial region of the cancer to predict the 
intra-tumor heterogeneity in this Challenge. However, undoubtedly, multi-region sequencing will 
provide more comprehensive characterization for the entire tumor [52], [53]. For example, in a 
collaborative research project [54], [55], we developed a state-space model based on the feature 
allocation framework and sequential Monte Carlo algorithm, using the mutation data from 
multi-region tumor samples to infer the subclonal structure. Second, we were provided with six 
training samples in this Challenge, which is obviously too small. With a larger set of training data, 
the model could be trained better. For instance, the phylogenetic relationships in the current 
training samples are quite simple, and hence our straightforward, heuristic approach for building 
phylogenetic trees (Materials and Methods) seems good enough, whereas in real situations it 
would be much more complicated. Last, the data we used come from synthetically derived tumors. 
Although the Challenge organizers designed sophisticated simulations of realistic tumor genomes, 
such as incorporating phasing of mutations, large-scale copy number changes, translocations, and 
replication timing, it is still not the real thing. It would be much better if we had single-cell 
sequencing data [56], [57] with good quality and adequate sequencing depth and breadth that could 




Chapter 3: Meta-analysis of Expression and Methylation Signatures 




Major psychiatric disorders, such as schizophrenia and bipolar disorder, and neurodegenerative 
diseases, such as Alzheimer’s and Parkinson’s, all pathologically relate to abnormalities in the 
brain [58]–[61] with different manifestations in each case, but the underlying etiologies remain 
largely elusive. Extensive research has implicated environmental factors in the pathogenesis of 
such neuropsychiatric disorders [62]–[66], operating through epigenetic mechanisms to change 
gene expression, thereby disrupting particular biological functions in brains. For example, in the 
case of several types of dementia, including Alzheimer’s disease, environmental influences have 
been associated with the risk of disorder, which can lead to epigenetic transformations, such as 
altering DNA methylation and histone modification, over time [67]. Furthermore, striking 
experimental evidence connecting environmental stress and pathogenic outcome has been 
provided by research on animals [68]–[70] (rodents and primates) and humans [71], [72] 
(monozygotic twins with discordant disease states), based on which the epigenome-based latent 
early-life associated regulation-based model [73] was proposed as a mechanistic explanation for 
the gene-environment interactions, indicating that accumulated environmental risk factors produce 
latent epigenetic changes.  
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In contrast, transcriptomes and DNA methylation patterns of different brain regions differ 
substantially [74], [75] across brain regions. In this study, we focused on one specific brain region, 
the prefrontal cortex (PFC), which has been implicated in the etiology of different neuropsychiatric 
diseases [76], [77].  
We reasoned that the co-expression and co-methylation modules can be used as signatures 
to represent some particular biomolecular events, and that the modules shared by different diseases 
indicate common mechanisms. Moreover, analyzing interrelationships between signatures can 
help further understanding of such mechanisms. For example, a significant association observed 
between some co-expression and co-methylation signatures can indicate a particular epigenetic 
regulation.  
For that purpose, we first assembled multiple publicly available gene expression and DNA 
methylation datasets obtained from postmortem adult PFC samples across six neuropsychiatric 
disorders along with healthy controls. We then identified a number of “consensus” PFC 
co-expression and co-methylation signatures present in similar forms across multiple datasets 
using an unsupervised methodology [78]. Integrative analysis of these signatures along with 
supervised analysis of available phenotypic associations suggested that a particular epigenetic 
abnormality could be involved in the pathogenesis of different neuropsychiatric illnesses. 
 
3.2 Materials and Methods 
3.2.1 Data availability and preprocessing 
Discovery data cohorts consisted of publicly available expression data and DNA methylation data 
of postmortem PFC samples from 426 subjects (242 cases, 184 controls) and 823 subjects (406 
cases, 417 controls), respectively. The details of sample information are shown in Table 3.1. Most 
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publicly available human postmortem PFC samples were obtained using the Affymetrix Human 
Genome U133 array and the Illumina HumanMethylation 450k beadchip for expression and DNA 
methylation, respectively. Because our multi-data-set algorithmic implementation works best with 
uniform data properties, we restricted the datasets to those types of profiling platform. We 
eliminated from consideration datasets representing repeated runs of the samples from the same 
subjects, thereby avoiding replicates in the data cohorts that we collected for consensus signature 
identification, which could have otherwise biased the results. We also required that the number of 
either cases or controls should be at least 10 for expression data and 15 for methylation data 
(because of the larger number of probes for the methylation platform). 
 
Table 3.1 Description of datasets assembled for consensus analysis. (a) Gene expression cohorts; 
(b) DNA methylation cohorts. 
 
BA Brodmann area, PFC prefrontal cortex (for which Brodmann areas not specified), HG-U133A Affymetrix Human 
Genome U133A Array, HG-U133-P2 Affymetrix Human Genome U133 Plus 2.0 Array, HM450 Illumina Infinium 
HumanMethylation450 Beadchip, SMRI Stanley Medical Research Institute.  
a. Cases consist of 11 bipolar disorder, 11 major depressive disorder and 11 schizophrenia patients. 
b. Cases consist of 31 bipolar disorder and 34 schizophrenia patients. 
 
 
Dataset Disease Platform Brain region 
Sample size 
(ctrl:case) 
Gene expression cohorts 
GSE5388 [79] Bipolar disorder HG-U133A BA9 31:30 
GSE17612 [80] Schizophrenia HG-U133-P2 BA10 23:28 
GSE20168 [81], [82] Parkinson’s HG-U133A BA9 15:14 
GSE21138 [83] Schizophrenia HG-U133-P2 BA46 29:30 
SMRI AltarC multiplea HG-U133A BA46/10 11:33 
SMRI Bahn multipleb HG-U133A BA46 33:65 
GSE54567/54568/54570 [84] Major depression HG-U133A BA9 42:42 
DNA methylation cohorts 
GSE49393 [85] Alcoholism HM450 BA9 23:23 
GSE59685 [86] Alzheimer’s HM450 PFC 24:56 
GSE61107 [87] Schizophrenia HM450 PFC 24:24 
GSE61380/61431 [88] Schizophrenia HM450 BA9 38:38 
GSE74193 [89] Schizophrenia HM450 BA46/9 240:191 
GSE80970 [90] Alzheimer’s HM450 PFC 68:74 
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We downloaded the raw datasets and preprocessed them as follows. Datasets with 
gene-expression values were profiled using either of two Affymetrix platforms, but we only used 
HG-U133A probes for analysis in this study so that every individual expression dataset contains 
the same probe set. The raw CEL files were log-transformed and RMA-normalized for each 
individual dataset with default settings, as implemented in the R Bioconductor affy package [91]. 
For DNA methylation analysis, we obtained β values from the methylated and unmethylated signal 
intensities for each individual dataset using the dasen function in the R Bioconductor wateRmelon 
package [92]. 
The validation datasets used in this study include additional microarray and RNA-seq 
datasets. The microarray datasets include GSE36980 for Alzheimer’s disease [93] and GSE49376 
for Alcoholism [85], which were not included in the consensus analysis because they were profiled 
on different platforms. We normalized them in the same way as we did for the Affymetrix 
microarray data. The RNA-seq datasets, covering four of the six neuropsychiatric diseases, include 
PFC samples from GSE68719 for Parkinson’s [94], GSE101521 for major depression [95], and 
bipolar disorder and schizophrenia samples as part of the BrainGVEX study (available on Synapse 
with accession number syn4590909) in the PsychENCODE Consortium [96]. For RNA-seq 
datasets deposited on Gene Expression Omnibus (GEO), we normalized the raw counts 
individually using DESeq2 [97], removed genes whose expression values were zero in more than 
half of the samples, and performed log2-transformation. For the BrainGVEX data, we downloaded 





3.2.2 Attractor-finding algorithm  
General version for individual datasets 
The attractor-finding algorithm is an unsupervised method to identify signatures of mutually 
associated features from a matrix containing values of features (rows) in different samples 
(columns). Therefore, using expression or methylation matrices, it identifies co-expression and 
co-methylation signatures, respectively. 
The details of the general attractor-finding algorithm can be found in previous work [78], 
[98]. Briefly, the algorithm uses an iterative procedure to collect mutually associated features, 
converging to the core (“heart”) of the underlying co-expression or co-methylation mechanism. 
The association measure we used is based on the mutual information (MI) [99] that generally 
captures even nonlinear relationships between variables. To outline the process in the case of gene 
expression data, it starts from a “seed” (e.g., the expression of one particular gene). In the first 
iteration, all genes are ranked by their MI with the seed gene, and a “metagene” is created as a 
hypothetical gene whose expression values, for each sample, are equal to the weighted average of 
the expression values of all genes, where each weight is defined as a function of the MI of that 
gene with the seed gene. Each subsequent iteration updates the metagene so that the weight of each 
gene in the new metagene is defined as a function of the MI of that gene with the previous metagene. 
The process is repeated until convergence to an “attractor metagene.” From the attractor metagene, 
we extract the top-ranked genes (those with the highest weights), together with a “score” (ranging 
from 0 to 1) for each of these genes, measuring the “strength” of the membership of that gene in 
the signature. If the strength of, say, the 10th ranked gene is > 0.5, this suggests that there is a 
strong co-expression involving at least ten genes, and that the genes with the highest scores in the 
attractor metagene point to the core of the biological mechanism underlying that co-expression. 
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The same attractor algorithm can be applied to types of mutually correlated features other than 
genes. Therefore, more generally, the term “metagene” is an example of a “metafeature,” and it 
has also been implemented in MATLAB’s metafeatures function in the Bioinformatics Toolbox. 
Using every available gene as seed identifies a limited number of strong co-expression 
signatures, each resulting in identical form from numerous seed genes. For methylation data, due 
to the excessively high number of methylation probes, we used a heuristic procedure for the 
exhaustive search to reduce computational complexity. The procedure, together with additional 
selection and filtering criteria for the validity of converged signatures to represent significant 
biological events (such as having a sufficient number of genes with high scores in each of them) 
are detailed in www.synapse.org/#!Synapse:syn5909000. 
Probe-selection version for datasets with multiple probes for same gene 
Different platforms have different probe designs and sometimes each gene may have multiple 
measurements at different probes that often highly correlate with each other rather than 
representing independent gene isoforms. This can create a bias of favoring genes with multiple 
probes. To avoid this kind of bias, we analyzed the gene expression and methylation datasets by 
using a “probe-selection” version of the attractor-finding algorithm. As in the general algorithm, 
the probe-selection algorithm computes the association between the metafeature and all the 
available probes. The probe-selection algorithm has an additional step, however, in which for each 
feature it only selects one probe having the highest weight. Only those probes are used to update 
the metafeature in the next iteration. Due to the nature of the probe-selection algorithm, probes not 




Consensus version for multiple datasets 
To identify common signatures shared across multiple diseases, we used a “consensus” version of 
the attractor-finding algorithm, which simultaneously considers all individual datasets. In each 
iteration for generating a new metafeature, the association measure of each feature with the 
immediately preceding metafeature is evaluated as the weighted median of the corresponding 
association measures taken from the individual datasets. The weights are proportional to the 
number of samples included in each individual dataset. In one particular case, because the sample 
size of one methylation dataset (GSE74193) is one magnitude higher than those of the other 
methylation datasets, we divided it into smaller subsets based on samples’ processing plates, 
resulting in eleven individual methylation datasets used in the final consensus analysis. The above 
probe-selection and consensus methods of the attractor-finding algorithm are also detailed in 
www.synapse.org/#!Synapse:syn5909000. 
Filtering consensus signatures by analyzing their presence in individual datasets 
After identifying the consensus signatures, for each dataset, we used the average value (expression 
or methylation) of the top ten probes of all the consensus signatures as seeds to run the 
probe-selection attractor-finding algorithm, thereby deriving the particular individual versions of 
each signature. Then, we evaluated the pairwise overlap between each individual signature and 
each consensus signature in terms of gene symbols using the hypergeometric test (one-tailed 
version of Fisher’s exact test). We accepted the presence of a consensus signature in the individual 
dataset if its overlap with the individual signature version that it derived was the most significant 
(i.e., with the smallest P value) compared with its overlaps with other individual signatures of this 
dataset and had P value less than 0.05. After obtaining results for all individual datasets, we 
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removed any consensus signatures that were not present in the majority (i.e., more than half) of 
the individual datasets from the final list.  
Code Availability 
The code for generating the signatures discussed in this study is available at 
https://github.com/zky0708/Meta-analysis-of-neuropsychiatric-disorders. 
 
3.2.3 Statistical analysis  
As described above, each attractor signature defines a ranked set of genes along with selected 
probes depending on their scores. We used the average values of the top ten probes to represent 
the levels of corresponding signatures. For DNA methylation profiles, we transformed the 
methylation to M values as recommended [100] and then took the average. 
Cell type specificity analysis 
We assessed the significance of cell type enrichment with the hypergeometric test by comparing 
the cell type markers and the genes for which the mapped probes had scores higher than 0.5 in the 
signature. To correct for multiple testing, we adjusted the resulting P values with the false 
discovery rate (FDR) method using the p.adjust R function with parameter method = “fdr”. A 
signature is considered enriched for one specific cell type if it has significant overlap (P < 0.05) 
with each reference list of markers. 
Functional enrichment analysis 
We used the Molecular Signatures Database (MSigDB) with the gene set enrichment analysis 
(GSEA) software [101] (v6.2) to explore the biological functions or processes overrepresented in 
specific gene sets, such as the identified co-expression and co-methylation signatures. The 
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MSigDB contains eight major annotated gene set collections, including Gene Ontology (GO) gene 
sets and hallmark gene sets, etc. The analysis outputs the hypergeometric P value and the FDR 
q value according to the Benjamini–Hochberg procedure as an estimate of statistical significance 
for the overlap with these gene sets. To provide evidence of translational impact, we used the 
STRING [102] database (v10.5) to investigate the protein–protein interactions (PPIs) and protein 
functional analysis in each signature. For each signature, we used genes with scores higher than 
0.5 as inputs, and limited their size to 500. FDR q values < 0.05 were considered significant. 
Association identification 
To investigate the association of the signatures with disease diagnosis, we used the linear 
mixed-effects (LME) model to evaluate the significance of disease association for each type of 
disorder. Because multiple data cohorts of the same disorder were included, we used a random 
effect of study to consider the inter-study variability. To account for potential confounding effects, 
we evaluated results derived from two LME models, as follows: 
Model 0: Signature ~ Diagnosis + (1|Study) 
Model 1: Signature ~ Diagnosis + Age + Gender + PMI + (1|Study) 
where PMI = postmortem interval. 
In Model 0, we obtained a “pure” significance of disease association without including 
other covariates, and in Model 1, we obtained a “confounder-adjusted” disease significance by 
treating age, gender, and postmortem interval, the covariates which are available in most of the 
datasets, as fixed effects. We used the lmer function implemented in the lme4 R package [103] to 
fit the model using restricted maximum likelihood (the default in lme4), and derived P values using 
Satterthwaite’s degrees of freedom method with the lmerTest R package, as suggested for 
producing acceptable Type I errors even for smaller sample sizes [104]. We further considered the 
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potential confounding effects of other covariates (antipsychotics dose, method of death, substance 
abuse, and smoking) which are only available in some datasets. We assessed their association with 
corresponding signatures separately in individual datasets by performing one-way analysis of 
variance. We also performed the Mann–Whitney U test, a nonparametric approach, to evaluate the 
disease association for each disease in the individual datasets to confirm the results. In all cases 
above, we set the threshold of statistical significance for P values to 0.05. 
We examined the correlation between same-type signatures (i.e., expression to expression, 
methylation to methylation) using the Pearson’s correlation test. The “expression-methylation” 
(E-M) correlation between one co-expression signature and one co-methylation signature cannot 
be directly evaluated by using the same method because no expression and methylation data come 
from identical samples. As an alternative, we evaluated the E-M interrelationship by comparing 
gene membership, taking a significant overlap as an indication that indeed, methylation of the 
intersection genes affects the expression of those genes. We used the hypergeometric test to 
evaluate the significance of the overlap between the mapped gene symbols of the two signatures, 
for which the total gene pool was the intersection of the genes included in both expression and 
methylation platforms. The resulting P values were adjusted by the FDR method. Similarly, we 




The consensus attractor finding (Materials and Methods) of the combined data cohorts identified 
three consensus co-expression signatures and five consensus co-methylation signatures, referenced 
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here as E1 through E3 and M1 through M5, respectively. The top-ranked probes and the mapped 
gene symbols of each signature appear in Table 3.2.  
 
Table 3.2 Top probes in each PFC consensus signature. Three columns are shown for each 
signature that denote the probe ID, gene symbols, and scores (rounded to four decimal places) 
for the top 15 probes. (a) Consensus co-expression signatures, E1 to E3. (b) Consensus 
co-methylation signatures, M1 to M5. 
(a) 
 
E1 E2 E3 
Probes Genes Scores Probes Genes Scores Probes Genes Scores 
209300_s_at NECAP1 0.8463 202800_at SLC1A3 0.8772 209769_s_at SEPT5-GP1BB 0.8030 
212990_at SYNJ1 0.8265 207761_s_at METTL7A 0.8247 217696_at FUT7 0.7826 
202854_at HPRT1 0.8228 203908_at SLC4A4 0.8194 214122_at PDLIM7 0.7676 
208841_s_at G3BP2 0.8092 202936_s_at SOX9 0.8180 216940_x_at YBX1 0.7666 
213745_at ATRNL1 0.8031 201667_at GJA1 0.8092 214105_at SOCS3 0.7537 
204552_at INPP4A 0.8022 212230_at PPAP2B 0.7954 209979_at ADARB1 0.7524 
201889_at FAM3C 0.8009 201876_at PON2 0.7926 209730_at SEMA3F 0.7439 
205352_at SERPINI1 0.8005 212377_s_at NOTCH2 0.7898 216680_s_at EPHB4 0.7425 
205280_at GLRB 0.7963 203296_s_at ATP1A2 0.7888 207306_at TCF15 0.7417 
209274_s_at ISCA1 0.7942 206465_at ACSBG1 0.7684 216345_at ZSWIM8 0.7385 
211763_s_at UBE2B 0.7915 209210_s_at FERMT2 0.7624 206824_at CES1P1 0.7325 
202670_at MAP2K1 0.7909 221796_at NTRK2 0.7613 216821_at KRT8P11 0.7305 
218042_at COPS4 0.7866 212850_s_at LRP4 0.7505 202828_s_at MMP14 0.7244 
221207_s_at NBEA 0.7864 205328_at CLDN10 0.7432 216076_at L3MBTL1 0.7219 










M1 M2 M3 
Probes Genes Scores Probes Genes Scores Probes Genes Scores 
cg10717149 SLC25A14 0.9911 cg22655232 PPP1R2P9 0.9784 cg26765599 NMRAL1 0.9040 
cg04317640 SLC16A2 0.9910 cg11049634 BCOR 0.9778 cg06081917 BFAR 0.9013 
cg16221895 EDA 0.9908 cg05130312 LOC286467 0.9740 cg17032990 MAP4K4 0.8983 
cg14191108 MAOA 0.9907 cg14372935 PIR 0.9722 cg02473439 CCAR1 0.8979 
cg10981178 ZBTB33 0.9899 cg06780606 EDA 0.9716 cg02193425 FAM50B 0.8972 
cg26505478 CUL4B 0.9893 cg09791535 GPC4 0.9714 cg02313013 TMCC3 0.8942 
cg23696472 TSPYL2 0.9892 cg09192294 LAS1L 0.9701 cg00489902 POLE 0.8926 
cg05806018 AFF2 0.9890 cg07801607 ZMAT1 0.9696 cg10521450 SH3PXD2A 0.8922 
cg11594566 LINC00086 0.9884 cg04690567 PHF8 0.9683 cg02041593 SEMA5B 0.8917 
cg10201390 DYNLT3 0.9882 cg00098732 HS6ST2 0.9662 cg00245075 GALNT6 0.8911 
cg20749341 LONRF3 0.9881 cg12653510 XIST 0.9662 cg19885979 TRIM26 0.8902 
cg22164912 GNL3L 0.9877 cg27551771 KIAA1210 0.9639 cg00452755 RCC1 0.8900 
cg20766178 NHSL2 0.9875 cg01037726 PNCK 0.9627 cg02450267 MOG 0.8876 
cg18989810 DUSP9 0.9874 cg04704683 POF1B 0.9617 cg23384027 NFE2 0.8875 
cg22604777 MAGEH1 0.9874 cg08209935 ARMCX5 0.9602 cg02713352 B4GALNT1 0.8874 
M4 M5 
Probes Genes Scores Probes Genes Scores 
cg12268888 FAM198A 0.8628 cg12547839 UBE2O 0.8539 
cg09063372 HDGF 0.8506 cg22330763 SLC29A1 0.8421 
cg11150308 SRP68 0.8505 cg04101806 AFF3 0.8203 
cg16129988 UQCRC1 0.8468 cg23400122 MSRA 0.8179 
cg11371394 TGFBRAP1 0.8406 cg26218110 BAHCC1 0.8153 
cg04233747 PRELID2 0.8403 cg25119743 CELF2 0.8023 
cg03330867 TELO2 0.8398 cg06372223 SLC7A5 0.8023 
cg04426297 B3GAT3 0.8394 cg24897320 CYB561D1 0.8008 
cg24695828 ZNF566 0.8324 cg14706739 DMTN 0.7987 
cg01923255 ATG14 0.8321 cg08202720 PER2 0.7983 
cg26897054 DEDD2 0.8317 cg17518776 PACSIN1 0.7970 
cg11111696 ZNF438 0.8312 cg20318252 MSI2 0.7966 
cg25426560 DHX16 0.8309 cg24107728 LRP8 0.7962 
cg05623562 RBFA 0.8300 cg08506743 NTM 0.7943 




Considering the gender-related differences in gene expression and methylation, including 
the fact that there are such differences in neuropsychiatric disorders [105], we first investigated if 
any signature is related to gender. Among the co-methylation signatures, we found that M1 and 
M2 were purely gender-related (due to the presence of both genders in the data; Figure 3.1), 
consistent with their top-ranked genes being almost exclusively located in sex chromosomes. For 
example, XIST, one of the top genes of signature M2 (see Table 3.2b), plays a critical role in the 
process of X-chromosome inactivation in mammalian females, an early developmental mechanism 
through which one of the X chromosomes is silenced by the combination of DNA methylation and 
histone modifications to provide dosage compensation [106]. Because they are otherwise unrelated 
with disease phenotypes, we do not include them in the following analyses. 
 
 
Figure 3.1 Gender-related PFC consensus co-methylation signatures (M1 and M2) in different 
disorders. The x axis and y axis show the methylation levels of M1 and M2 signatures, 
respectively, calculated as the average β values of the top ten CpG sites in each signature. Female 
and male samples are represented in red and black colors, respectively. The plots are labelled 
with the associated neuropsychiatric disorders. (a) Alcohol use disorder, of dataset GSE49393. (b) 






Co-expression and co-methylation signatures include contributions from several distinct 
cell subpopulations in the heterogeneous brain tissues, from cell types such as neurons, astrocytes, 
oligodendrocytes, and immune cells, which can further decompose into cell subtypes. Because 
their corresponding probes have the property that their expression or methylation values tend to 
have higher or lower values in concordance, it is likely that some of these signatures reflect the 
relative abundance of such a subpopulation, which varies from sample to sample. Alternatively, 
co-expression or co-methylation may be due to the varying activation of a particular mechanism 
in the same subpopulation, as may result, for example, when the expression levels of multiple 
genes are affected by their simultaneous methylation. 
Therefore, we investigated which among the consensus signatures we found are 
predominantly due to the varying abundances of particular cell types across samples. To identify 
the enrichment of the consensus signatures in cell-type-specific genes, we made use of two 
published gene lists of such gene markers derived from single cell analyses for reference [107], 
[108] (Materials and Methods). The first reference list is taken from a study providing a 
classification of human brain cells into six major types [107]. The second reference list comes 
from a study providing a full list of marker genes of nine cell types found in mouse cortex [51]. 
Although not resulting from human tissues, these extensive and detailed listings from mice are 
useful for additional scrutiny and validation. The results of enrichment analysis of cell type 
markers using the two lists were highly consistent (Table A.1). All signatures were found enriched 
for some specific cell types except E3 and M4. 
For the co-expression signatures, this analysis revealed that signature E1 is enriched for 
neuronal markers (P = 0.0033 using the human markers). As the mouse cortex gene set contains 
particular neuronal subtypes, we further found that E1 has the highest overrepresentation of 
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markers for the interneuron subtype (P = 0.0018). On the other hand, we found that signature E2 
is highly enriched for astrocyte-specific markers (such as SOX9, GJA1 ranked at the top) in both 
gene lists (P = 2.2 × 10-13 using the human markers and P = 1.4 × 10-16 using the mouse markers). 
 
 
Figure 3.2 Negative correlation between cell type specific PFC consensus co-methylation 
signatures (M3 and M5) in different cell populations. The x-axis and y-axis show the 
methylation levels of the M3 and M5 signatures, respectively, calculated as the average β values 
of the top ten CpG sites in each signature. The samples come from the dataset GSE41826, which 
includes methylation data of separated neurons (red), separated glia (green), and mixed (black 
for manually mixed and blue for bulk samples) from healthy human PFC tissues. The proportion 




For the co-methylation signatures, we found that signatures M3 and M5 are enriched for 
markers of glia and neurons, respectively (Table A.1) and strongly and negatively correlated with 
each other (Pearson’s r < −0.75, P < 1.2 × 10-8; Table A.2). We validated this finding by checking 
the methylation levels of M3 and M5 in an independent human PFC methylation dataset of isolated 
neurons and nonneurons as well as manually mixed and bulk samples [109] (GSE41826; Figure 
3.2). Moreover, M3 was found associated with the co-expression signature E2 (P = 0.010; 
Materials and Methods), which is consistent with the aforementioned facts that E2 was 
overrepresented in astrocyte markers and M3 was enriched for different subtypes of glial cell 
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including astrocytes. Taken together, these findings indicate that M3 and M5 reflect the relative 
abundances of neurons versus glial cells in samples, which are negatively associated, by including 
particular hyper- and hypo-methylated loci in these two subpopulations. 
We evaluated the signatures’ associations with disease diagnosis considering potential 
confounding effects (Materials and Methods; Appendix A.2). As a result, we observed that the 
co-expression signatures E1 and E2 showed concordantly significant associations in more than 
one type of neuropsychiatric disorders (Table A.4), and these associations are unlikely to be 
spurious due to confounding factors. Moreover, both signatures were enriched for PPI networks 
(P < 1.0 × 10-16 for E1, P = 8.4 × 10-14 for E2). Specifically, E1 was broadly downregulated in 
several types of diseases, a topic discussed in detail in the next section. 
The other signature, E2, was found upregulated in schizophrenia (P = 1.8 × 10-3) and 
bipolar disorder (P = 2.1 × 10-3). One of the GSEA top hits suggested that E2 is also enriched for 
genes found upregulated in brains with Alzheimer’s disease [110] (FDR q value =1.8 × 10-19). 
Finally, we observed a substantial overlap between E2 and an astrocyte-related co-expression 
module (named “CD4”) that was recently found to positively associate with multiple psychiatric 
disorders [111] (P = 1.1 × 10-114). Functional annotation analysis indicated enrichment for 
biological pathways related to nervous system development and glial cell differentiation. 
The most significant E–M association was between signatures E1 and M4 (P = 1.9 × 10-4; 
see full E–M association P values in Table A.3), which share a large proportion of genes in 
common. We first discuss the co-expression signature E1, which we found to be the one most 
significantly associated with disease diagnosis among all the identified consensus signatures. We 
observed significant downregulation of E1 in the presence of disease in several types of 
neuropsychiatric disorders except for depression and alcohol use disorder, and we confirmed this 
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striking association using validation datasets (Table 3.3). We took into account the potential 
confounding effects of all available traits (including age, gender, manner of death, substance abuse, 
and antipsychotic treatment usage, etc.), and results suggested that the significant disease 
association we identified in signature E1 may not be confounded by these factors (Materials and 
Methods; Appendix A.2). 
 
Table 3.3 Disease association of co-expression signature E1. Shown are the P values of 
association with diagnosis in different disorders resulting from the LME models (Materials and 
Methods) for signature E1. Columns annotated by “Model 0” and “Model 1”, represent the “pure” 
and “confounder adjusted” cases, respectively. 




















Diseases E1(Model 0) E1(Model 1) 
Schizophrenia 1.7×10-3 1.1×10-3 
Bipolar disorder 3.8×10-5 3.3×10-5 
Parkinson’s 0.013 0.040 
Major depression 0.19 0.13 
Diseases E1(Model 0) E1(Model 1) 
Schizophrenia 0.011 0.011 
Bipolar disorder 0.014 0.014 
Parkinson’s 7.1×10-4 0.016 
Alzheimer’s 0.018 0.026 
Alcohol use disorder 0.99 0.99 
Major depression 0.92 0.89 
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The disease-associated downregulation of signature E1 is supported by its large overlap 
(using the genes for which the scores in E1 are higher than 0.5) with previously identified 
differentially expressed gene sets in different illnesses. For instance, E1 genes are overrepresented 
in a set of genes identified as downregulated in the PFC of patients with schizophrenia [112] 
(P = 9.1 × 10-7). Furthermore, the top GSEA result for E1 revealed significant enrichment for genes 
downregulated in the brain from patients with Alzheimer’s disease [110] (FDR q 
value = 3.0 × 10-317). Finally, many common genes were included in E1 and a neuronal module 
(named “CD13”) that had been found downregulated in multiple psychiatric illnesses [111] 
(P = 2.3 × 10-40). These findings strongly suggest that the downregulation of the consensus 
co-expression signature E1 represents an important biological event occurring in the brain 
affecting different neuropsychiatric disorders. 
As previous studies indicated [110], [112], and in concordance with the GSEA results of 
signature E1, some downregulated genes are involved in biological processes related to neuronal 
functions including neurotransmitter transport, signaling pathways and various energy metabolism 
processes. In contrast, as mentioned previously, E1 was found enriched in neuronal markers, 
particularly of the interneuron subtype, which allows for a possibility that the disease correlation 
of E1 is caused by the variances of this particular cell population, as was the case for signature E2. 
To elucidate in what ways E1 is related to interneurons and associated with disease, we designed 
the experiment as described below. 
In the experiment, we made use of the set of interneuron density markers whose expression 
levels significantly and positively correlated with the density of CALB1-positive GABAergic 
interneurons [113], which also appeared as the second top GSEA hit for signature E1 (FDR q 
value = 5.9 × 10-250). The null hypothesis was that the downregulation of E1 observed in patients 
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with disease is caused by the decreasing population of interneurons, in which case we should 
expect to see that the disease association decreases when we remove the markers for interneuron 
density from the E1 gene list. Therefore, we compared the disease association of the subset of E1 
genes without those interneuron markers, referenced as “Set E1/Interneuron” with that of the E1 
signature. As a result, the disease association for the Set E1/Interneuron became stronger in most 
cases, rejecting the null hypothesis (Table 3.4, see columns named “E1” and “E1/Interneuron”). 
This finding suggests that the strong disease association of signature E1 in various 
neuropsychiatric disorders is not caused by the allocation of interneuron subpopulation in samples. 
We then looked at the significant overlap of genes found between the co-expression 
signature E1 and the co-methylation signature M4, which implies an underlying epigenetic 
regulation mechanism. We selected the overlapping genes between the E1 and M4 signatures 
(using genes with scores > 0.5), referenced as “Set E1∩M4”, and ranked them by the minimum of 
their scores in E1 and M4 gene lists so that the top gene has the highest minimum score (Table 
3.5 shows the ranked list of the top 15 genes of Set E1∩M4 whereas the full list can be found in 
Table A.5). We evaluated the disease association of Set E1∩M4 using the average expression 
values of the top-ranked ten genes in the set and compared them with the case of E1 itself. As a 
result, we observed overall enhancement of the association with diagnosis in the cases of the Set 
E1∩M4 (Table 3.4, columns labeled “E1” and “E1∩M4”). This result suggests that the 
co-methylation signature M4 contributes to refining the co-expression signature E1 with respect 






Table 3.4 Strengthened disease association compared with E1 alone. Shown are the 
confounder-adjusted P values of association with diagnosis in different disorders for three 
E1-related gene sets in the discovery data. Columns “E1,” “E1\Interneuron,” and “E1ÇM4” 
represent the cases for the E1 signature alone, the subset of E1 genes without GABAergic 








Table 3.5 Top ranked genes in the Set E1ÇM4. This table shows the top 15 overlapping genes 
between signatures E1 and M4, ranked by the minimum of their scores in the two signature gene 
lists. The four columns represent the gene symbols, corresponding probe IDs in E1 and M4 


















Diseases E1 E1\Interneuron E1ÇM4 
Schizophrenia 1.1×10-3 4.6×10-4 2.5×10-4 
Bipolar disorder 3.3×10-5 1.1×10-5 2.7×10-6 
Parkinson’s 0.040 0.086 0.032 
Major depression 0.13 0.12 0.050 
Gene Symbols Probes in E1 Probes in M4 Min scores 
CAND1 208838_at cg17524854 0.7499 
DYNC1LI1 217976_s_at cg25390230 0.7253 
ATP5A1 213738_s_at cg10619144 0.6912 
EFR3A 212150_at cg09396107 0.6786 
MEAF6 218165_at cg03112782 0.6774 
PNMA1 218224_at cg23681213 0.6772 
SEC23A 212887_at cg02056847 0.676 
ZNHIT3 212544_at cg09922935 0.6697 
PPP2R5C 201877_s_at cg08393828 0.6676 
NDUFAB1 202077_at cg21989500 0.6675 
EIF1B 201738_at cg25839330 0.6672 
PPP3CA 202429_s_at cg00302793 0.6667 
SLC30A9 202614_at cg09414773 0.6599 
UQCRC2 212600_s_at cg03031583 0.6595 
RGS7 206290_s_at cg24472496 0.6592 
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Furthermore, regarding the co-methylation signature M4 itself, we found it has a unique 
attribute among all nongender-related consensus co-methylation signatures in that it contains a 
remarkably high proportion of methylation probes located at promoter-associated regions 
(P = 8.0 × 10-149) and CpG islands (P = 0) when compared with overall sites for the methylation 
array (Table A.6), implicating its function of epigenetic regulation. 
To understand the biological functions represented by the E1–M4 signature, we applied 
functional annotation analysis to the intersection genes. First, significant enrichment of PPIs 
(P = 2.2 × 10-16) indicates the meaningful biological connections and regulatory functions among 
the proteins encoded by these genes. The small GTPase superfamily was the top hit by assessing 
the overlap with InterPro protein domains and features database [114]. Among the results of GSEA 
analysis, the set of genes downregulated in brains with Alzheimer’s disease [110] remains at the 
top (FDR q value = 9.7 × 10-115). Overrepresentation also emerged in sets of genes having at least 
one occurrence of highly conserved motifs matching binding sites for transcription factors SP1 
(FDR q value = 3.1 × 10-25) and LEF1 (FDR q value = 5.6 × 10-14), which may provide hints about 
the nature of the underlying epigenetic mechanism. Moreover, we found that stress-related 
biological processes (GO) were enriched with genes in the E1–M4 signature (FDR q value < 10-6). 
We further confirmed that these stress-related gene sets were also overrepresented in the respective 
E1 and M4 signatures, but not in any of the other consensus signatures (Table A.7). 
Along with the significant E–M interrelationship and strong disease association, these 
findings collectively suggest that the E1–M4 signature pair represents some stress-induced 






To investigate the underlying pathological mechanism(s) common to various neuropsychiatric 
diseases, we performed a meta-analysis of the expression and methylation data of postmortem PFC 
samples collected from patients with six different neuropsychiatric disorders and healthy controls 
(Table 3.1). By using an unsupervised approach, we identified several consensus co-expression 
and co-methylation signatures present in similar forms across different datasets and diseases 
(Table 3.2). By scrutinizing these signatures’ disease associations and interrelationships, this study 
revealed some biological abnormalities strongly associated with disease diagnosis.  
For example, we identified an astrocyte-related co-expression signature, E2, which was 
observed up-regulated in patients with schizophrenia and bipolar disorder, and functional 
enrichment analysis also indicated its overlap with genes found to be up-regulated in Alzheimer’s 
disease. Previous researchers have suggested that the changes in expression of astrocyte markers 
could link to neuroinflammation in these diseases [115], [116]. We did not observe such a positive 
association in other disorders. Taking major depressive disorder as an example, our results showed 
that, on the contrary, E2 is negatively, though not very significantly, associated with disease 
diagnosis (Table A.4). Indeed, researchers have reported persistent decreases in astrocyte-specific 
markers in patients with major depression [117], indicating disease association with decreased 
density or hypofunction of astrocytes; also experimental evidence provided understanding of the 
underlying pathogenic mechanism using animal models [118].  
Our work resulted in the derivation of several co-expression and co-methylation signatures 
using an algorithm designed to point to the core of the underlying mechanisms, which suggests 
that the top genes of such signatures are more biologically accurate than traditional clustering 
methods. However, the main feature of this study is the examination of the interrelationships 
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between such expression and methylation signatures in search of epigenetic mechanisms. 
Understanding disease-associated epigenetic mechanisms may provide opportunities to develop 
novel therapeutic options. 
Using this approach, our main finding was the novel discovery of a significant 
interrelationship between the co-expression signature E1 and co-methylation signature M4, which 
indicates an epigenetic relationship. On one hand, the signature E1 is enriched for interneuron 
markers and we provided evidence that the derivation of the signature is due to a variation in the 
expression levels of such interneurons, rather than a varying abundance of their subpopulation. On 
the other hand, E1 was found strongly down-regulated in multiple types of neuropsychiatric 
diseases (Table 3.3). The disease association becomes further strengthened when we consider the 
shared genes between E1 and M4 (Table 3.4), suggesting that this sharper disease-associated 
signature is related to an epigenetic mechanism involving the E1–M4 genes (Table 3.5). The 
overrepresentation of promoter-associated regions and CpG islands in the corresponding genes of 
M4 also complements its role in epigenetic regulation. Future experimental research on those 
genes has the potential to uncover the details of the biological mechanism underlying the 
epigenetic signature and leading to therapeutic applications. 
We did not, however, observe a significant disease association of the signature in major 
depressive disorder and in alcohol use disorder, suggesting that their diagnoses are often 
independent of the underlying biological mechanism. This is consistent with the notion that there 
is comorbidity between depression and alcohol use disorder [119]. Such differences reflect the 
heterogeneity of neuropsychiatric disorders. For example, major depressive disorder has small 
heritability compared with other disorders [120].  
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In addition, functional annotation analysis of the E1–M4 genes revealed the enrichment of 
stress-related biological processes. Although the genes highlighted under the identified GO terms 
may reflect internal cellular processes, most gene activities are attributed to pathways involving 
exogenous stressors. Notably, researchers have investigated and implicated stress response and 
related epigenetic regulation mechanisms in the brain in neuropsychiatric diseases [65], [66], [121], 
[122], raising the possibility that these effects are driven by psychiatry-relevant psychosocial 
stressors or other relevant biological processes and should be investigated in future studies.    
Our findings should be interpreted in light of some caveats. Although we have controlled 
for all known confounders, unmeasured variables specific to disease states may influence results 
to some degree in epigenomic and transcriptomic studies. The identified mechanisms in this study 
may well be causal and important underlying features to disease etiology, but the chance persists 
that this is not true.  
In summary, our integrative data mining and analysis of some of the identified consensus 
co-expression and co-methylation signatures suggest the presence of a stress-related epigenetic 






Chapter 4: Imputing Single-cell RNA Sequencing Data from 
Correlations in Two Dimensions 
 
4.1 Introduction 
The explosive growth of single-cell RNA sequencing (scRNA-seq) data in recent years has led to 
important biological discoveries [123]–[125]. Nevertheless, due to the low starting amounts of 
transcripts, a problem manifesting in scRNA-seq data is the “dropout effect,” which results in 
many false-zero values in the data [126], posing challenges for downstream analyses [127]. To 
alleviate this problem, in addition to efforts to resolve technical issues, such as improving 
transcript capture efficiency, imputation algorithms specific to scRNA-seq data have been 
developed for predicting those missing values due to dropouts. Some methods have been proposed 
integrating imputation with other processing tasks, such as normalization, batch effect correction, 
clustering [128], [129]. It is important, however, that imputation is also treated in isolation as 
simple dropout correction, so that users can have the option of building analysis pipelines 
processing dropout-corrected data specifically designed for their own particular tasks.  
The following five imputation methods — MAGIC [130]; SAVER [131]; scImpute [132]; 
DrImpute [133]; and VIPER [134] — are among the most widely used methods, relying on 
predicting values based on information from either similar cells or similar genes, using various 
approaches. MAGIC constructs a Markov affinity matrix for cells based on the cell-to-cell 
Euclidean distances, and, in addition to imputing zero entries, is also a data smoothing method 
designed to correct all expression values. ScImpute involves a step to cluster cells into 
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subpopulations using Euclidean distances, whereas DrImpute provides a similar method, making 
use of Pearson and Spearman correlations. SAVER identifies genes that are most predictive of the 
gene of interest using a penalized regression model, and VIPER uses a similar technique on cells.  
These methods, however, are constrained by several restrictions. For example, scImpute 
and DrImpute require users to provide an estimate of the number of subpopulations as input, which 
is difficult to specify in real applications. SAVER is designed specifically for unique molecule 
index (UMI)-based scRNA-seq data, and VIPER assumes a zero-inflated Poisson mixed model for 
gene expression levels across cells, which may not be true for all scRNA-seq protocols. Finally, 
according to several comparative studies [131], [132], [134], [135], MAGIC tends to remove true 
biological variation and induce spurious correlations. 
 
4.2 Materials and Methods 
4.2.1 Data preprocessing and normalization 
The input of 2DImpute is a normalized scRNA-seq expression data matrix with or without log 
transformation. In the former case, the output imputed data of 2DImpute remains in a 
log-transformed version. In the latter case, we take a log transformation on the normalized count 
matrix with a pseudo-count of 1, that is, log2(norm_count + 1), by following the common practice 
in scRNA-seq analyses [136], which will be used  in the following imputation in the 2DImpute 
algorithm. The imputed version would be converted back to count matrix by de-logging and 
subtracting the pseudo-count as output. However, it should be noted that the log transformation 
and the pseudo-count choice could have effects on the downstream analyses, extensively discussed 
in [137]. For analyses in this paper, we performed data normalization as follows. Given a 
scRNA-seq count matrix, if the unit is UMI count, we first performed the library size normalization 
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defined as dividing by the cell’s total UMI counts and then multiplying by 10,000. If the unit is a 
normalized measurement such as TPM (transcripts per kilobase per million reads), we used the 
counts directly. Apart from library size normalization, users can choose from advanced scRNA-seq 
normalization methods such as scran [138], SCnorm [139] and scater [140]. 
 
4.2.2 2DImpute algorithm 
The algorithm composes four steps: Step 1 predicts whether a zero in the expression matrix is true 
or false so that only the predicted false zeros are imputed in the subsequent steps. In Step 2, we 
apply the unsupervised “attractor metagenes” algorithm [78] to identify co-expression signatures. 
These signatures involve a particular subset of genes. In Step 3, we perform imputation on the 
predicted false zeros in those genes, making use of information from the co-expressed genes in the 
same signature. In Step 4, we imputed the predicted false zeros of the remaining genes, making 
use of information from similar cells as well as of the imputed values in Step 3, as we found that 
imputation based on co-expressed genes is more accurate than that based on similar cells 
(Appendix B.1) and performance improves by following the above steps sequentially. Following 
is a detailed description of these steps. 
Step 1. Identify dropouts from zeros 
Each zero in the expression matrix is predicted to be either false (dropout), or true, as follows: We 
first identify a set of “similar cells” to the cell to which it belongs, in the sense of having, as much 
as possible, the same genes shown as expressed (with positive values) or not expressed (with zero 
values). To measure similarities between cell m and cell n, we use the Jaccard index based on 






The set of similar cells consists of the cells for which the above measure is greater than 0.5. 
If the number of such cells is less than ten, we leave the zero unchanged in the following steps 
because we do not have sufficient confidence. Intuitively, if we find that a gene is expressed in 
many similar cells, this increases the chance that it is a dropout event, compared to a gene for 
which similar cells tend to have zero values. Therefore, using the above set of similar cells, we 
calculate the proportion among them for which each gene is expressed (> 0) as an indicator. We 
then predict that the zero is a dropout event to be imputed in the subsequent steps if this indicator 
exceeds a cutoff threshold t (default t = 0.2, sensitivity analysis can be found in Appendix B.2); 
otherwise we predict that it is a true zero. 
Step 2. Find gene co-expression signatures using the “attractor metagenes” algorithm 
To leverage the information among strongly co-expressed genes, we apply the unsupervised 
pattern-finding algorithm identifying attractor metagenes [78] on the expression matrix. Because 
the genes in an attractor signature tend to express high or low values across cells simultaneously, 
we impute dropout values (in Step 3) using information from the other co-expressed genes. 
Briefly, the attractor finding algorithm finds mutually associated genes from an expression 
matrix in an iterative manner, converging to the core of the underlying co-expression mechanism. 
The association measure used is the normalized mutual information (MI) [99] (Appendix B.3), 
which captures general relationships (linear and nonlinear) between variables. Using the 
expression vector of a seed gene as input, the algorithm converges to an “attractor” in the form of 
a list of ranked genes together with “scores” (ranging from 0 to 1) for each of these genes, 
measuring the strength of the membership of that gene in the signature.   
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Because we are only interested in imputing genes that contain predicted dropouts, we 
restrict the “seed pool” used to find attractors to those genes. We further restrict the seed pool by 
excluding seed genes whose highest MI with all other genes is smaller than 0.2, because such genes 
will not be members of strong co-expression signatures. We run the attractor algorithm using the 
findAttractor() function implemented in the “cafr” R package with the default exponent parameter 
a = 5 and threshold of convergence epsilon = 10-4. We process genes in the seed pool in decreasing 
order of their standard deviations. For computational efficiency, once we obtain a converged 
attractor signature, we further remove any genes having scores greater than that of the seed in use 
in the signature from the seed pool, because it is unlikely for those genes to converge to a different 
attractor when used as seeds.  
The above process results in a number of attractors. Finally, we modify the list of attractors 
according to two criteria: First, we filter out any attractor for which the score difference between 
the first and second top genes is greater than 0.2, indicating that the attractor is dominated by the 
top gene. Second, we keep only attractors for which the score of the fifth-ranked gene is at least 
0.4, suggesting a sufficiently strong co-expression mechanism involving at least five genes. 
Step 3. Impute dropouts in genes that are involved in the identified attractors 
In this step, we impute dropouts in the genes whose scores are greater than 0.4 in at least one 
identified attractor. For cases where a gene is found in multiple attractors, we assign the gene to 
the one in which it has the highest score, and remove the gene from the other attractor lists. Thus, 
each attractor now contains a non-overlapping set of genes. If any attractor ends up having fewer 
than five genes after this processing, we remove it from the following analysis. We then quantify 
the relationship between each gene involved in an attractor and the top genes of that attractor with 
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a linear regression model (Appendix B.4) and use the fitted model to predict the dropout values in 
the gene.  
Specifically, for each gene in an attractor, we define C0 to be the set of cells in which there 
are predicted dropouts, and S0 to be the set of the top 20 genes (or all the involved genes if there 
are less than 20) in the attractor excluding that gene. To obtain appropriate predictor variables and 
samples for model fitting, we select genes and cells as described below. For genes, we remove 
genes whose expression is zero in all the cells in set C0 from set S0, and define S1 to be the set of 
the remaining genes. For cells, we select only those in which the genes in set S1 are all expressed 
(> 0), and define C1 to be the set of those cells. To ensure a sufficient sample size for model fitting, 
we require the number of cells in set C1 to be at least equal to either (i) 50 or (ii) 10N, where N is 
the number of genes in set S1. If neither of the two criteria are satisfied, we remove the bottom 
ranked gene from set S1, and update the cells in set C1 accordingly, repeating the above process 
until one of the criteria is met. This method provides the predictor variables (set S1) and samples 
(set C1) to fit the linear regression model. 
Furthermore, to mitigate the negative effects of extreme values on the estimation of 
regression coefficients, we perform winsorization on the expression vectors of genes in set S1 
across cells in set C1 as follows: Extreme values are defined as those that lay outside the 1.5×IQR 
limits, where IQR stands for interquartile range, which is equal to the difference between the 75th 
and 25th percentiles. We cap these extreme values by replacing those outside the lower limit with 
the value of 5th percentile, and those that lay above the upper limit with the value of 95th percentile. 
Finally, we fit a linear regression model where the dependent variable is the expression 
value of gene i and the predictor variables are expression values of genes in set S1 using cells in 
set C1. Then, we predict the expression values of gene i in set C0 with the fitted model, that is, 
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𝐸p!" = q 𝛽#𝐸#"
#∈8","∈9#
 
where 𝐸p!" denotes the predicted expression value of gene i in cell j, 𝐸#" is the observed expression 
value of gene k in cell j, and 𝛽# is the corresponding coefficient for predictor variable (gene k). 
Any negative predicted values are replaced by zeros.  
Step 4. Impute remaining dropouts using cell-to-cell relationships 
This step finalizes imputation by making predictions for the remaining predicted dropouts that 
were not imputed in the previous step, making use of the already imputed values. For each cell j 
containing unimputed predicted dropouts, we define G to be the set of genes for which the dropout 
events are detected. By using genes excluding those in set G as variables, we calculate the Pearson 
correlation between cell j and all the other cells. For each gene i in set G, we find the top k (default 
k = 10; Appendix B.5) cells with the highest Pearson correlations. Then, we compute the mean of 
the expression values of gene i in those cells, excluding cells in which gene i is not expressed (= 
0), as the imputed value for the expression of gene i in cell j. 
 
4.2.3 Figures of merit  
To assess and compare the performance of different imputation methods both quantitatively and 
qualitatively, we used three different figures of merit on log-transformed expression data, as 
described below. 
The first figure of merit is quantitative. By supposing the dropout rate of each gene follows 
a double exponential function exp(-0.1 × mean_expression2) [132], [141], where the 
mean_expression is the mean level of non-zero expression of that gene, we identified a subset of 
non-zero entries for each gene on a Bernoulli distribution, defined by the dropout rate for that gene 
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in each dataset. Then, we selected several percentages (2%, 5%, 10% and 20%) of these entries 
randomly and masked them to zeros, followed by applying different imputation methods. To 
measure imputation accuracy, we compared the imputed and actual values of those masked entries 
by different metrics, including Pearson correlation, Root Mean Squared Error (RMSE) and Mean 
Absolute Error (MAE). We calculated Pearson correlation using only imputed entries because 
some imputation methods identify and impute only a subset of zeros, the effect of which has 
already been evaluated through RMSE and MAE.    
The ground truth specifying which, among all the zeros, are false and in need of imputation 
is, in general, unknown. However, occasions exist in which particular genes are known to be 
expressed in all cells by design, as in fluorescence-activated cell sorted (FACS) cells. The second 
figure of merit uses such cases to evaluate the extent to which imputation methods accurately 
predict that the zeros in those genes are dropouts and impute them to relatively high expression 
levels while retaining a balanced separation between predicted true and false zeros for the other 
genes. In such FACS-purified datasets, we examined and compared the expression distribution 
shapes of the corresponding gene used for fluorescent labeling, as well as some other genes known 
to only express in specific cell subpopulations (such as cell type markers) before and after 
imputation. To visually compare distribution shapes, we scaled the imputed values of each method 
so they have the same maximum and minimum levels.  
The above experiment can assess the balance of separating true and false zeros by 
imputation for a few particular genes in real datasets with known truth. To provide a more 
comprehensive assessment of the ability to distinguish true zeros from dropout events, in the 
absence of actual ground truth for all zeros, we used Splatter [142] to simulate scRNA-seq datasets. 
We estimated the simulation parameters for three different profiling platforms (10x, InDrop, 
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Smart-Seq2) from the count matrices of the three scRNA-seq datasets analyzed in the main text. 
Following the approach described in [135], each simulated dataset contained 1,000 cells split into 
two or ten equally sized groups and 5,000 genes. For all the combinations of platforms and cell 
groups, we generated ten simulations, resulting in 60 simulated datasets in total. We applied the 
same data preprocessing method to the simulated count matrices as we did for other analyses in 
this paper, and then imputed each dataset by each method. To score the accuracy of identifying 
spurious zeros for different imputation methods, we calculated the sensitivity (i.e., the proportion 
of actual false zeros that are correctly identified), the specificity (i.e., the proportion of actual true 
zeros that are correctly identified) between the imputed values, and the truth of all zeros, as well 
as the “balanced accuracy” defined as the average of sensitivity and specificity. 
The third figure of merit evaluates imputation methods based on their ability to recover 
known cell-to-cell relationships in datasets of known cell composition consisting of distinct cell 
types. We calculate two types of pairwise cell correlations, one between cells of the same cell type 
(“intra-cell”) and the other between cells of different cell types (“inter-cell”). Because random 
dropouts tend to decrease associations, proper imputation approaches should be able to strengthen 
the intra-cell, rather than the inter-cell correlations. We calculated the pairwise cell-to-cell 
Spearman and Pearson correlations for each such data matrix, including the original one without 
imputation and the ones imputed by different methods, using only genes with non-unimodal 
distributions. A gene is informative for cell specific analysis only if it has different expression 
levels among cells of different types/states. We performed Hartigan’s dip test [143], [144] for each 
gene using the function dip.test in the R package diptest. We then adjusted the resulting P values 
for unimodality for multiple testing with the false discovery rate (FDR) method by using the 
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p.adjust R function with parameter method = “fdr”. Genes with FDR adjusted P value < 0.1 were 
retained for this analysis. 
 
4.2.4 Other imputation methods for comparison  
All imputation methods are available in R packages. The package versions used in this paper are 
specified as follows: scImpute (v0.0.9), SAVER (v1.1.2), MAGIC (v2.0.3), DrImpute (v1.0), and 
VIPER (v0.1.1). We performed experiments following the default or recommended settings. 
 
4.2.5 Data availability  
All scRNA-seq datasets used in this paper are publicly available. For two of them, we used subsets 
of cells to ensure comparable sample sizes (~ 3,000) for all the datasets, facilitating the comparison 
of algorithms with respect to their performance on different scRNA-seq platforms. For each dataset, 
we preprocessed the data as described above. We then applied conservative filtering of genes with 
extremely low expression based on the preprocessed data so the retained genes were expressed 
(>1) in at least 10 cells. The step of removing low abundance genes was recommended before the 
application of imputation and other downstream analyses [131], [145]. 
• 10x dataset [146]: We downloaded the dataset from the 10x Genomics website 
https://support.10xgenomics.com/single-cell-gene-expression/datasets/. It contains a 
50%:50% mixture of 3,388 Jurkat cells and 295T cells.  
• InDrop dataset [147]: We downloaded the dataset from Gene Expression Omnibus (GEO) 
with accession number GSE114725. The dataset contains CD45+ cells from eight primary 
breast carcinomas from patients. We selected cells from patient BC6 consisting of 3,498 
CD45+ cells from one primary breast carcinoma. 
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• Smart-Seq2 dataset [148]: We downloaded the dataset from GEO with accession number 
GSE115978. The dataset contains scRNA-seq profiles from 33 human melanoma tumors 
comprising 17 newly collected patient tumors and 16 previously reported patient tumors 
[149]. We selected cells from the new cohort, which consists of 2,987 cells.   
 
4.3 Results 
Here we propose a novel scRNA-seq imputation approach, called 2DImpute (Materials and 
Methods). In brief, 2DImpute distinguishes dropout-suspected events from true biological zeros 
by using Jaccard distance-based cell-to-cell relationships and then imputes those predicted 
dropouts by leveraging the interrelationships across genes and cells as follows. 2DImpute first 
identifies co-expression signatures using the unsupervised “attractor metagene” algorithm [78] and 
imputes spurious zeros for the genes that are involved in such signatures. 2DImpute then performs 
imputation on the remaining dropout values based on cell-to-cell relationships through k nearest 
neighbor regression across cells, making use of the previously imputed values of the co-expressed 
genes.  
Because scRNA-seq datasets profiled from different protocols have distinct characteristics 
[150], analyzing the performance of imputation on data profiled by various protocols could provide 
a more comprehensive assessment for each method. Therefore, to evaluate methods we selected 
recently published, high-quality, real scRNA-seq datasets [146]–[148] profiled on three prevalent 
scRNA-seq protocols (Smart-seq2, inDrop and 10x Genomics Chromium). Each dataset contains 
approximately 3,000 cells and all data were preprocessed accordingly before imputation 
(Materials and Methods). To evaluate and compare different imputation techniques, we used 




Figure 4.1 Evaluation of 2DImpute in comparison to other imputation methods. (a) Imputation 
accuracy measured by Pearson correlation between imputed and actual values for non-zero 
values, artificially masked to zero. The masking ratio (2%, 5%, 10%, and 20%) is defined as the 
percentage of a set of non-zero entries in the data matrix (Materials and Methods). (b) Violin 
plots showing the distributions of universally expressed gene CD45 and the macrophage-specific 
gene CD68 before (annotated as “unimputed”) and after imputation. (c) Bar plots corresponding 
to the mean pairwise cell-to-cell Spearman correlation in data without and with imputation, in 
which error bars corresponds to 1 SD; “293T” and “Jurkat” represent the “intra-cell” correlations 




We measured the accuracy of recovering artificially masked non-zero entries, which were 
introduced by assuming the dropout rate of each gene follows a double exponential distribution of 
the mean expression level of that gene (Materials and Methods). Figure 4.1a and Figure B.1 
show the accuracy of recovering such values in each of the three real scRNA-seq datasets measured 
by different metrics: Pearson correlation, RMSE and MAE. The results of 2DImpute had the 
highest accuracy, whereas other methods showed inaccurate and unstable performance when 
applied to different datasets.  
We also evaluated the accuracy of distinguishing true from false zeros, using two methods 
(Materials and Methods). First, we compared imputation methods in the particular case of 
FACS-purified cells [147], in which case we had the ground truth that all zeros in the fluorescent 
labeling gene (which is CD45 in this case) were false and in need of imputation. Figure 4.1b 
shows the results for CD45 and the macrophage-specific marker CD68. 2DImpute is the only 
method that combines (i) the correct prediction that all zeros in CD45 were dropouts and had them 
imputed, while also (ii) retaining a separation between predicted true and false zeros for other 
genes (e.g., macrophage marker CD68). Other imputation methods had various performance issues. 
For example, scImpute left a large number of zeros in CD45 unchanged; SAVER barely corrected 
the distribution shape for gene CD45 (but only shifted zeros to very small values); MAGIC created 
an artificially bimodal distribution in the case of CD45+ cells, contrary to ground truth. In contrast, 
DrImpute imputed all the zeros for macrophage marker CD68 to relatively high values, without 
exception; VIPER imputed a large fraction of zeros in CD68 to relatively low values, thereby 
destroying the sharp bimodal distribution consistent with the partial proportion of macrophages in 
the cell population. We also validated the results in other genes of the same dataset (Figure B.2).  
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Moreover, we validated the results by using other independent FACS-purified scRNA-seq 
datasets: GSE108989 [151] and GSE123814 [152]. GSE108989 contains expression profiles of 
individual T cells from 12 treatment-naïve patients diagnosed with colorectal adenocarcinoma. We 
selected cells from patient P0825, which had the largest number of cells available (= 1,215). 
GSE123814 contains scRNA-seq profiles of malignant, immune and stromal cells from 11 patients 
with advanced basal cell carcinoma before and after anti-PD-1 treatment. We selected cells from 
patient su006 after treatment which contains all three types of cells and the number of cells is 
largest (= 4,051). We normalized and applied imputation methods on these two datasets, and 
evaluated the results using the second figure of merit (Figure B.3), which reached the consistent 
conclusion that 2DImpute effectively predicts and imputes true zeros and leaves false zeros 
unchanged.  
 
Table 4.1 Accuracy for different imputation methods using Splatter-simulated data. Median 
scores of specificity, sensitivity, and balanced accuracy measured for different methods of 
identifying false zeros using simulated data. Asterisks (*) indicate scores < 0.5. 
Metrics Platforms 2DImpute scImpute SAVER MAGIC DrImpute VIPER 
Specificity 
10x 0.62 0.27* 0* 0* 2.2´10-4* 0.56 
InDrop 0.82 0.70 0* 0* 9.0´10-4* 1 
Smart-seq2 0.58 0.26* 0* 0* 8.7´10-7* 0.47* 
Sensitivity 
10x 0.76 0.94 1 1 1 0.8 
InDrop 0.52 0.62 1 1 1 9.3´10-4* 
Smart-seq2 0.78 0.95 1 1 1 0.86 
Balanced 
Accuracy 
10x 0.69 0.61 0.5 0.5 0.5 0.68 
InDrop 0.67 0.66 0.5 0.5 0.5 0.5 






Second, to provide a more comprehensive assessment with the ground truth for true versus 
false zeros, we also simulated 60 scRNA-seq datasets using Splatter [142], taking into account 
variations in scRNA-seq profiling platforms and composition of cell subpopulations (Materials 
and Methods). We imputed each simulated dataset with each imputation method. Because the 
performance differences between datasets of different cell subpopulations are negligible, we listed 
the results grouped by platforms (Table 4.1). 2DImpute had the highest balanced accuracy, and 
was the only method that simultaneously exhibited high sensitivity and high specificity (> 0.5). 
Furthermore, we assessed imputation methods by examining their ability to recover 
cell-to-cell relationships by only strengthening “intra-cell” correlations (Materials and Methods). 
We used the 10x scRNA-seq dataset, including a 50%:50% mixture of Jurkat cells and 293T cells 
[146], for which the cell labels were provided in the original publication based on the expression 
of gene markers. Figure 4.1c shows the average values of the two types (intra-cell and inter-cell) 
of pairwise cell-to-cell Spearman correlation, calculated using the data before and after imputation. 
The mean intra-cell and inter-cell correlations in the unimputed data were about 0.4 and 0.3, 
respectively. On one hand, the majority of methods successfully reinforced the intra-cell 
correlation to a much higher level (> 0.6) except for DrImpute after imputation. On the other hand, 
2DImpute properly reduced the inter-cell correlation to nearly zero. By contrast, MAGIC, SAVER, 
VIPER, and scImpute greatly increased inter-cell correlations to levels higher than 0.5. The worst 
performance was from MAGIC, where the mean inter-cell correlation reached 0.6, suggesting it 
eliminated inherent biological variation. Using Pearson correlation as the metric gave the 
consistent results (Figure B.4).  
In addition to cell-to-cell correlation, we also designed experiments following the approach 
described in [131], [135] to assess the effects of imputation on gene to-gene correlation. Using the 
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same 10x scRNA-seq dataset [146], we evaluated the differential expression of each gene between 
the two cell types (Jurkat cells and 293T cells) using a Mann-Whitney U test on the 
log-transformed normalized data. Genes with a raw P value > 0.2 were then permuted across cells 
to eliminate any residual biological signals. Permuted counts were obtained by de-logging and 
de-normalizing the permuted expression to avoid library-size confounders. We applied each 
imputation method to the permuted data after normalization. We then identified the N = 50 most 
and least differentially expressed genes from the permuted data before imputation, respectively, 
the gene-to-gene correlations of which we could confidently consider true. We calculated the 
pairwise Pearson correlations for these 2×N = 100 genes in the data before and after imputation, 
and then compared them using the correlation matrix distance (CMD) [153] as the metric. The 
CMD is a measure of the distance between two correlation matrices and ranges from 0 (equal) to 
1 (maximum difference). As shown in Table B.1, the worst performance (largest CMD = 0.14) 
was observed in case of MAGIC, indicating spurious correlations between genes were induced, 
whereas the results for all the other imputation methods had smaller CMDs with the true 
correlation matrix. We also examined cases where N = 100, and the results were consistent with 
the overall values of CMD increased a bit. We also assessed the effects of imputation on 
gene-to-gene correlations by designing experiments based on permuted real data. 
In another manner, we further confirmed the tendency of MAGIC to induce spurious 
correlations. Following the approach detailed in [134], we examined the change of gene expression 
variability after imputation in the Smart-seq2 dataset [148] using the coefficient of variation (CV) 
to quantify the variability for each gene. It is expected that the CV across cells after imputation 
would be either equal to or greater than the CV of non-zero values before imputation. All methods 
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except MAGIC effectively preserved the cross-cell gene expression variability, however MAGIC 
reduced the variability for the majority (> 52%) of genes. 
Imputation techniques are not required to be implemented in real time; therefore low 
computational complexity is not a fundamental requirement as long as it is reasonable. We 
compared the computational efficiencies of various methods, concluding that 2DImpute has 
reasonable complexity (Table 4.2). We found that MAGIC was the fastest method, whereas 
VIPER had particularly slow performance in some cases. 
 
Table 4.2 Computing time for different imputation methods. Imputation was applied to 
different scRNA-seq datasets. The number of genes (p), number of cells (n) and proportion of 
zeros in each dataset are listed. Computing time was evaluated on Intel Core i7-4970 CPU @ 
3.60GHz. For methods that enabled parallel computing, we used two cores when running the 
algorithm. 
Datasets 
Platform 10x InDrop Smart-seq2 
Dimensions (p × n) 3774 × 3388 2318 × 3498 16238 × 2987 
Zero proportion 36.7% 70.5% 71.3% 
Computing Time (in hours) 
2DImpute 4.2 2.4 11.5 
scImpute 2.6 0.94 2.9 
SAVER 1.1 0.55 10.4 
MAGIC 0.061 0.019 0.25 
DrImpute 1.9 2.8 1.8 







In conclusion, each of the prevalent methods has several drawbacks, whereas 2DImpute tends to 
balance the benefit of effective imputation and the risk of over-imputation. 2DImpute distinguishes 
dropouts from true zeros and leverages interrelationships both among genes and among cells. The 
algorithm does not require prior knowledge of the number of cell subpopulations, does not make 
arbitrary assumptions of statistical models for expression distributions, and is robust for use in 
various prevalent scRNA-seq platforms. Improvements in scRNA-seq imputation techniques will 
benefit subsequent analyses in many aspects, including network analysis, which is currently 







Chapter 5: Single-cell RNA-seq Analysis Reveals the Pan-cancer 
Transformation of Adipose-derived Stromal Cells into 
COL11A1-expressing Metastasis-associated Fibroblasts 
 
5.1 Introduction 
This research follows up our previous work in 2010 [21], in which we had identified a cancer 
stage-associated signature by comparing the gene expression of lower-stage to that of higher-stage 
cancer samples. The signature was remarkably similar across cancer types, as long as the 
corresponding staging threshold was properly set, different in each cancer type. The genes of the 
signature, with prominent presence of collagen COL11A1, activin A (INHBA), and 
thrombospondin-2 (THBS2), would never be overexpressed in samples below that 
cancer-type-specific threshold, but were overexpressed in a subset of profiled samples above that 
threshold. For example, the signature only appeared in ovarian cancer samples of at least stage III, 
in colon cancer samples of at least stage II, and in breast cancer samples of at least invasive stage 
I (but never in samples from carcinoma in situ).  
We had referred [21] to those particular COL11A1-expressing cancer-associated 
fibroblasts as metastasis-associated fibroblasts (MAFs), and had demonstrated the striking 
consistency of the signature. For example, Table 5.1 shows the top 15 genes ranked in terms of 
fold change for three different cancer types (breast [154], ovarian [155], and pancreatic [156]) 
using bulk microarray data provided in papers published independently in 2006, 2007, and 2008, 
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respectively. The breast cancer data compared invasive ductal carcinoma versus ductal carcinoma 
in situ (supplementary data 3, “up in IDC” of the paper [154]); the ovarian cancer data compared 
metastatic tissue in the omentum with primary tumor (table 2 of the paper [155]); and the 
pancreatic data compared whole tumor tissue versus normal pancreatic tissue (table 1 of the paper 
[156]). The four genes COL11A1, INHBA, THBS2, and COL5A2 appear among the top 15 in all 
three sets (P = 6×10-23 by hypergeometric test [157]). The actual P value is much lower than that 
because, in addition to the above overlap, ten additional genes (COL10A1, COL1A1, COL5A1, 
FAP, FBN1, FN1, LOX, MFAP5, POSTN, and SULF1) appear among the top 15 in at least two 
of the three sets (and are highly ranked in all three sets). This demonstrates that the signature, to 
which we still refer as the MAF signature, is well-defined and associated with an important 
universal biological mechanism in cancer. We had also found [21] that gene COL11A1 can serve 
as a proxy for the full signature, suggesting it is expressed in the final stage of the underlying 
process and, based on that, we had deposited a representative 64-gene “multicancer invasiveness” 
signature in GSEA.  
In this work, using techniques from systems biology, we show that these fibroblasts are 
adipose-derived, which explains the above stage association as resulting from the interaction of 
cancer cells with the adipose microenvironment: This metastasis-associated biological process 
occurs, under some circumstances, as part of an interaction when tumor cells encounter the adipose 
microenvironment. Indeed, adipose tissue is encountered when ovarian cancer cells reach the 
omentum (stage III); after colon cancer has grown outside the colon (stage II); and in breast cancer 






Table 5.1 Top 15 ranked genes in terms of fold change (FC) for three different cancer types 
revealing the metastasis-associated fibroblastic signature. Shown are the rankings, reported by 
the authors, for breast, ovarian, and pancreatic cancers. We eliminated multiple entries of the 
same gene (keeping the one that appears first) and dashes. Genes shared in all three cancer types 
are highlighted in green whereas genes appearing twice are highlighted in yellow. 
 
  Breast Ovarian Pancreatic 
Rank Gene FC Gene FC Gene Log2FC 
1 COL11A1 6.50 COL11A1 8.23 INHBA 5.15 
2 COL10A1 4.07 COL1A1 5.67 COL10A1 5.00 
3 MFAP5 3.73 TIMP3 5.52 POSTN 4.92 
4 LRRC15 3.61 FN1 5.40 SULF1 4.63 
5 INHBA 3.44 INHBA 4.94 COL8A1 4.60 
6 FBN1 3.43 EFEMP1  4.86 COL11A1 4.40 
7 SULF1 3.35 DSPG3 4.36 CTHRC1 4.38 
8 GREM1 3.35 COL5A2 4.07 COL1A1 4.12 
9 COL5A2 3.22 LOX 4.03 THBS2 3.97 
10 LOX 3.22 MFAP5 4.01 HNT 3.90 
11 COL5A1 3.08 POSTN 3.97 CSPG2 3.87 
12 THBS2 2.99 COL5A1 3.95 WISP1 3.80 
13 LAMB1 2.97 THBS2 3.91 FN1 3.69 
14 FAP 2.96 FBN1 3.90 COMP 3.53 
15 SPOCK 2.91 FAP 3.84 COL5A2 3.38 
 
Since then, numerous research results have been published on the invasiveness-associated 
properties of COL11A1 and the other top genes of the signature in many individual types of solid 
cancer, some of which also observed that the signature is associated with resistance to therapy 
[158]–[164]. However, the origin and underlying mechanisms responsible for the generation of 
those pan-cancer fibroblasts have remained unclear. Single-cell technology provides a unique 
opportunity to further scrutinize the evolving expression of each gene in each individual fibroblast. 
In this follow-up work, we perform data analysis of single-cell RNA-seq (scRNA-seq) data, 
demonstrating a continuous transition in a path that starts from adipose-derived stromal cells 
(ASCs) and leads to COL11A-expressing MAFs, referenced as the “ASC to MAF transformation.”  
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We show that the ASC population from which this transformation originates is rich in 
fibroblastic markers such as LUM and DCN, as well as adipose-related genes such as APOD and 
PTGDS, and has stem-like properties, evidenced by gene set enrichment analysis. We also show 
that this population is naturally present in adipose tissue and gradually transforms as a result of 
interactions with tumor cells, so they start expressing genes such as RARRES1 and SFRP4, 
eventually obtaining an activated fibroblastic phenotype expressing COL11A1, INHBA, and 
THBS2. 
Our computational analysis includes two different methods (Materials and Methods), 
validating each other: We applied attractor analysis [165], [166] in the various datasets, identifying 
the gene expression profile of the dominant fibroblastic population in individual samples. We also 
applied trajectory inference analysis using the Slingshot algorithm [167]. We used publicly 
available scRNA-seq datasets (Materials and Methods) from five different cancer types. We gave 
particular emphasis to one of those datasets [168], from pancreatic ductal adenocarcinoma 
(PDAC), because it is particularly rich, containing gene expression profiles of 57,530 pancreatic 
cells taken from 24 PDAC tumor samples (T1–T24) and 11 normal control pancreatic samples 
(N1–N11). For example, using attractor analysis, we established that the dominant fibroblastic cell 
population in each of the eleven normal samples was of the ASC type described above. We also 
analyzed the attractor signatures of each of the tumor datasets, producing an observed continuous 
gene expression change in the dominant fibroblastic cell population as the biological mechanism 
proceeds. Using trajectory inference analysis, we validated the above results by producing 
trajectories starting from the point representing the normal ASCs, passing through intermediate 
states, eventually reaching the final state of COL11A1-expressing MAFs.  
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Finally, we validated these results with other cancer types (head and neck, ovarian, lung, 
and breast), suggesting that the metastasis-associated ASC-to-MAF transformation, involving the 
same participating genes, is present in all solid cancer types. 
 
5.2 Materials and Methods 
5.2.1 Data availability  
We downloaded the processed count matrix of the PDAC dataset [168] from the Genome Sequence 
Archive with accession number CRA001160. The four validation datasets of other cancer types 
are also publicly available: head and neck squamous cell carcinoma (HNSCC) [169] 
(GSE103322), ovarian [170] (GSE118828), lung cancer [171] (E-MTAB-6149 and 
E-MTAB-6653), and breast cancer [172] (GSE118389). We excluded samples from lymph nodes. 
The numbers of patients included in these datasets are 35 (PDAC), 18 (HNSCC), 9 (ovarian), 5 
(lung), and 6 (breast).  
 
5.2.2 Data processing and cell identification  
We applied the Seurat (v3.1.4) [173] R package to process the gene expression matrix and 
characterize the cell type identity for each scRNA-seq dataset. The count matrix was normalized 
and log-transformed by using the NormalizeData function. We selected the 2,000 most variable 
features and then performed principal component analysis, followed by applying an unsupervised 
graph-based clustering approach. We used default parameter settings in all the above steps except 
that we set the resolution parameter in the FindCluster function to 1.0 to increase the granularity 
of downstream clustering. To identify differentially expressed genes for each cluster, we used the 
FindMarkers function. To characterize the identity of mesenchymal cells in each dataset, we made 
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use of the expression of known markers: LUM, DCN, and COL1A1 for fibroblasts, RGS5 and 
ACTA2 for pericytes. 
For the smaller datasets (ovarian and breast), we performed clustering once on all cells for 
mesenchymal cell identification.  For datasets of larger size (PDAC, HNSCC, and lung), we 
applied “two-step clustering” to ensure accuracy: The first step was initial clustering in individual 
samples. Then we excluded samples with very few (< 20) detected fibroblasts and pooled the 
mesenchymal cells of the remaining samples together for a second clustering, which resulted in 
the final set of mesenchymal cells for the dataset. For the PDAC dataset, we included an additional 
step to remove low-quality cells by retaining cells for which at least one of the corresponding 
markers had expression levels ≥ 3.  
 
5.2.3 Mutual information  
Mutual information (MI) is a general measure of the association between two random variables 
[99]. We used a spline-based estimator [174] to estimate MI values, and normalized so the 
maximum possible value is 1. The details of the estimation method are described in the paper 
introducing the attractor algorithm [165]. We used the getMI or getAllMIWz function implemented 
in the cafr R package with parameter negateMI = TRUE.  
 
5.2.4 Attractor-based analysis  
To a single dataset, we applied the attractor finding algorithm using the findAttractor function 
implemented in the cafr R package [165] with the gene LUM as seed. The exponent (a) was set to 
different values for scRNA-seq datasets profiled from different protocols [175]. For the analysis 
of UMI-based (e.g., 10x) and full-length-based (e.g., Smart-seq2) datasets, we chose to use a = 3 
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and a = 5, respectively. Briefly, the attractor finding algorithm iteratively finds mutually associated 
genes from an expression matrix, converging to the core of the co-expression mechanism. The 
association measure used is the normalized mutual information (as described above), which 
captures the general relationships (including nonlinear effects) between variables. To find the 
consensus attractor for multiple datasets, we applied the consensus version of the attractor finding 
algorithm as described in [176]. In the consensus version, the association measures between genes 
are evaluated as the weighted median of the corresponding measures taken from the individual 
datasets. The weights are proportional to the number of samples included in each individual dataset 
in log scale. 
 
5.2.5 Trajectory inference analysis  
We selected the Slingshot [177] method for trajectory inference (TI) analysis, based on its 
robustness [178] and suggestions made by the benchmarking pipeline dynverse [178]. We used the 
raw counts as input and followed the Slingshot lineage analysis workflow (v1.4.0). To begin this 
process, Slingshot chose robustly expressed genes if they have at least 10 cells with at least 1 read 
for each. After gene filtering, we proceeded to full quantile normalization. Following diffusion 
map dimensionality reduction, we performed Gaussian mixture modelling to classify cells. For the 
final step of lineage inference analysis, we used the slingshot wrapper function. A cluster-based 
minimum spanning tree was used to describe the lineage. After analyzing the global lineage 
structure, we fitted a generalized additive model (GAM) for pseudotime and computed P values. 
Genes were ranked by P values and variances. After running Slingshot, we identified genes with 
expression values that significantly varied over the derived pseudotime by using a GAM, allowing 
the detection of non-linear patterns in gene expression. 
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5.2.6 Statistical analysis 
P value evaluation by permutation test  
We evaluated the significance of the consistency of N different attractors of size M as follows. We 
randomly selected M genes from the 24,005 genes to generate a random gene set, and we created 
N such random gene sets. Each time, we counted the number of genes common in all N gene sets, 
and we repeated this process ten million times. In these ten-million experiments, it never occurred 
that one or more genes were common in all N gene sets. Therefore, the corresponding P value was 
less than 10-7. 
Differential expression (DE) analysis 
We applied the FindMarkers() function in Seurat to identify the DE genes between fibroblasts of 
different groups. DE genes with |log fold-change| > 0.25 and Bonferroni-adjusted P value < 0.1 
were considered as significant. The positive and negative DE genes were ranked separately in the 
absolute values of their log fold-change.  
 
5.3 Results 
5.3.1 Pancreatic ductal adenocarcinoma dataset (attractor method)  
The PDAC dataset [168] consists of 57,530 single-cell RNA-seq profiles from 24 PDAC tumor 
samples (T1–T24) and 11 normal control samples (N1–N11). We first identified the mesenchymal 
cells in all these samples (Materials and Methods) resulting in 6,267 fibroblasts and 5,342 stellate 
cells. 
To find the expression profile of the dominant fibroblastic population present in each 
sample, we applied the unsupervised attractor algorithm [165] on the set of mesenchymal cells for 
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each sample using the fibroblastic marker LUM as seed (Materials and Methods). The algorithm 
is iterative and designed to converge to the core (“heart”) of a co-expression signature, referenced 
as an “attractor metagene,” and has been previously used successfully in identifying features useful 
for breast cancer prognosis [166], [179]. Each attractor metagene is defined by a ranked set of 
genes along with their scores defining their corresponding strengths within the signature; therefore 
the top-ranked genes are the most representative of the signature. The seed gene is used for the 
first iteration of the algorithm, but any among the top-ranked genes in a co-expression signature 
will yield precisely the same attractor signature. In this case, all samples yielded strong 
co-expression signatures involving many genes corresponding to their dominant fibroblastic 
population, with strong overlap among them.  
Table C.1 shows the top 100 genes for each of the 34 samples (11 normal and 23 tumor 
samples, excluding sample T20 as it did not contain identified fibroblasts). Genes LUM, DCN, 
FBLN1, MMP2, SFRP2 and COL1A2 appear in at least 33 of the 34 samples, revealing a strong 
similarity shared by those fibroblastic expression profiles. This strong overlap is consistent with 
the continuous transformation process described below. 
 
Dominant fibroblastic population in the normal PDAC samples is adipose-derived: There was 
a remarkable similarity among the attractor profiles of the eleven normal PDAC samples, 
demonstrating they represent a gene expression pattern of a stable and uniform, normally occurring 
cell population. Specifically, the top 50 genes in the attractors of at least ten of the eleven normal 
samples shared 18 genes, listed by average rank: LUM, APOD, PTGDS, C7, DCN, DPT, SFRP2, 
FBLN1, CCDC80, FBLN5, C1S, CXCL12, C1R, PDGFRA, CFD, COL6A3, MGP, C3 (P < 10-7 
by permutation test). In addition to the canonical fibroblastic markers, several strongly expressed 
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adipose-related or stemness-related genes in the list, such as apolipoprotein D (APOD), adipsin 
(CFD), stromal cell-derived factor 1 (CXCL12) [180], dermatopontin (DPT), and PDGFRA [181], 
[182], revealing that these are adipose-derived stromal/stem cells. Consistently, Gene Set 
Enrichment Analysis (GSEA) [183] of these 18 genes identified the most significant enrichment 
(FDR q value = 5.38´10-29) in the “BOQUEST_STEM_CELL_UP” dataset of genes upregulated 
in stromal stem cells from adipose tissue versus the non-stem counterparts [184]. Table 5.2 
demonstrates the striking similarity among the eleven normal sample attractor metagenes by listing 
the 20 top-ranked genes for each sample and color coding for genes LUM, DCN, APOD, C7, and 
PTGDS. 
 
Table 5.2 Top 20 genes of the identified attractors for each PDAC normal sample (N1–N11). 






Rank N1 N2 N3 N4 N5 N6 N7 N8 N9 N10 N11
1 DCN LUM LUM C7 APOD LUM PTGDS C7 DCN MMP2 LUM
2 LUM DCN FBLN1 FBLN5 DPT DCN APOD LUM LUM APOD DCN
3 C7 C7 C7 LUM FBLN5 FBLN1 LUM DCN C7 LUM FBLN1
4 FBLN1 FBLN1 PTGDS DCN PDGFRA ADH1B FBLN1 APOD FBLN1 EFEMP1 SFRP2
5 MGP APOD C1S APOD CXCL12 DPT C7 FBLN1 APOD CTSK CFD
6 C1S MGP DPT PTGDS LUM ABCA8 ADH1B SFRP2 SFRP2 SFRP2 APOD
7 CCDC80 C1S PDGFRA FBLN1 COL6A3 C3 DPT PTGDS SERPINF1 PLTP MGP
8 PTGDS DPT APOD C1R PTGDS APOD COL6A3 CCDC80 PTGDS MGST1 SERPINF1
9 DPT CCDC80 SFRP2 DPT C7 MMP2 EFEMP1 FBLN5 GSN LSP1 CCDC80
10 C1R PTGDS DCN SRPX CCDC80 C1S PDGFRA C1S C1S FBLN1 C3
11 APOD FBLN5 CXCL12 FMO2 CFD C7 CXCL12 CXCL12 SEPP1 SPON2 ADH1B
12 SEPP1 SEPP1 C1R SEPP1 MRC2 PTGDS SCN7A C3 CCDC80 PTGDS PTGDS
13 FBLN5 COL1A2 COL6A3 CXCL12 FGF7 SFRP2 MMP2 CFD DPT SVEP1 C7
14 CXCL12 SFRP2 ADH1B CYR61 SFRP2 FBLN5 MEG3 C1R OLFML3 CXCL12 C1S
15 EFEMP1 SRPX SPON2 SFRP2 MARCKS C1R C1S MGP FBLN5 SCN7A CST3
16 COL1A2 SERPINF1 CFD CLEC11A LRP1 CXCL12 OLFML3 CFH C1R COL6A3 C1R
17 SFRP2 OLFML3 LAMA2 PDGFRA FMO2 CST3 SVEP1 COL6A3 PTN CCDC80 CXCL14
18 ALDH1A1 CST3 C3 NR2F1 NR2F1 MGP DCN SRPX MGP COLEC11 MMP2
19 CFD MEG3 FBLN5 C1S TNXB CCDC80 SFRP2 EFEMP1 ALDH1A1 PDGFRA GPNMB
20 COL6A3 C1R ABCA8 ABCA8 DCN MRC2 MRC2 SEPP1 PDGFRA HBP1 S100A4
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 To demonstrate that the ASC population is naturally occurring in the normal adipose tissue 
of all types, we referred to recent results from single-cell analysis of general human adipose 
tissue[185]. We found that one of the identified clusters (P5, table s2 of the paper [185]) has eight 
genes with zero adjusted P value. Six among those eight genes are LUM, DCN, APOD, MGP, 
PTGDS, and DPT, all of which are among the top-ranked genes in all eleven attractor signatures 
above, revealing that the corresponding cluster contains the ASC population identified above 
among the PDAC normal samples. 
 
Dominant fibroblastic population in the tumor PDAC samples exhibits a continuous 
transition from the normal adipose-derived stromal cells to COL11A1-expressing 
metastasis-associated fibroblasts. Despite retaining the same top-ranked fibroblastic marker 
genes, the attractor metagenes for the PDAC tumor samples have different rankings for other genes, 
and several new genes appear in the list (Table C.1). These changes can be seen as representing a 
continuous transition of the gene expression profile of a cell type that is gradually differentiated. 
Consistently, the attractor of one of the normal samples (N10) contains RARRES1 and THBS2, 
which are among the genes that appear in the attractors of nearly all tumor samples (see below). 
This suggests that these fibroblasts are in the initial stage of differentiation; therefore, sample N10, 
despite being diagnosed as normal, belongs to a patient in which some malignant cells have started 
interacting with the adipose microenvironment.  
Specifically, in the tumor samples the rankings of the adipose-related genes (such as APOD, 
PTGDS, C7, CFD, and DPT) eventually dropped, whereas many genes of the MAF signature (such 
as COL11A1, INHBA, THBS2, and COL10A1) rose to the top (consistent with our subsequent 
validation using trajectory inference analysis, referring to the same genes). The reduction of the 
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adipose-related gene expression became more prominent in the strongly COL11A1-expressing 
samples, suggesting these samples represent the final stage of differentiation. 
Therefore, to investigate the continuous transition of ASCs to MAFs, we partitioned the 34 
PDAC samples into three groups, considering whether the corresponding attractor included 
COL11A1 among the top 100 genes. Group 1 includes the eleven normal samples (N1 to N11). 
Group 2 includes twelve tumor samples not expressing COL11A1 (T1, T2, T3, T5, T10, T12, T13, 
T14, T16, T18, T19, and T24). Group 3 includes eleven cancer samples expressing COL11A1 (T4, 
T6, T7, T8, T9, T11, T15, T17, T21, T22, and T23). We then applied a consensus version of the 
attractor finding algorithm (Materials and Methods) and identified the “consensus attractors” 
representing the main state of the fibroblasts for each of the above three sample groups, so we 
could observe the genes whose ranking changed significantly during the transformation 
(Table 5.3).    
As expected from the previous analysis of all individual samples, there are many common 
genes, which demonstrated the continuity in the transition based on the similarity among the 
fibroblasts in all groups (e.g., LUM, DCN, FBLN1, APOD, SFRP2 and COL6A3 appear among 
the top 20 genes in all three groups). On the other hand, the groups have distinct gene rankings. 
Group 1 (normal samples) contains many adipose-related genes, as mentioned previously. Group 
3 contains, in addition to COL11A1, many among the MAF genes [21], such as THBS2, INHBA, 
MMP11, AEBP1, MFAP5, COL10A1, VCAN, and FAP, apparently representing the desmoplastic 
stroma present in pancreatic tumors. 
Because COL11A1 can be seen as a proxy of the final stage of the signature [21], we also 
ranked all genes aligned with their association with COL11A1 in each of the Group 3 patients 
using the measure of mutual information (Materials and Methods). Table C.2 shows the top 20 
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genes for each of them, in which we observed that genes MFAP5 and COL10A1 appear in all of 
them; in other words, their expression further increases, along with COL11A1, during the final 
stage. 
 
Table 5.3 Top 50 genes of the consensus attractors for three different PDAC sample groups. 
Group1: normal samples; Group 2: tumor samples not expressing COL11A1; Group 3: tumor 
samples expressing COL11A1. 
 
Rank Group1 Group2 Group3 Rank (cont'd) Group1 Group2 Group3 
1 LUM LUM COL1A1 26 ABCA8 PLXDC2 NTM 
2 DCN DCN COL10A1 27 COL1A2 COL1A1 NBL1 
3 FBLN1 APOD COL1A2 28 LAMB1 OGN ITGBL1 
4 C7 SFRP4 CTHRC1 29 SVEP1 C1S FN1 
5 APOD SFRP2 SFRP2 30 MEG3 PTGDS MFAP2 
6 PTGDS VCAN COL3A1 31 PCOLCE ITGBL1 RARRES2 
7 SFRP2 FBLN1 MMP2 32 NEGR1 TSHZ2 GJB2 
8 C1S MMP2 LUM 33 FGF7 PODN MXRA5 
9 CCDC80 PDGFRA VCAN 34 LRP1 SERPINF1 LOX 
10 MGP EFEMP1 THBS2 35 CYR61 OMD MEG3 
11 DPT RARRES1 COL6A3 36 ALDH1A1 COL10A1 MRC2 
12 CXCL12 FBLN5 DCN 37 EFEMP1 HSD11B1 HTRA1 
13 C1R ISLR COL11A1 38 FMO2 IGF1 PDPN 
14 FBLN5 COL6A3 APOD 39 CFH RP11-572C15.6 FBLN2 
15 C3 C3 SFRP4 40 PLTP LTBP2 C1QTNF3 
16 PDGFRA CCDC80 COL5A2 41 SLIT2 FBLN2 TMSB10 
17 SRPX CTSK FAP 42 MRC2 COL3A1 POSTN 
18 COL6A3 CTHRC1 FBLN1 43 SCN7A STEAP1 CDH11 
19 ADH1B CYP1B1 COL8A1 44 LAMA2 LXN MMP14 
20 CFD MEG3 COL5A1 45 TIMP1 BOC CCDC80 
21 OLFML3 COL1A2 AEBP1 46 COL6A2 MRC2 SULF1 
22 SERPINF1 MOXD1 MFAP5 47 CXCL14 LRP1 TMEM119 
23 MMP2 C7 INHBA 48 LTBP4 THBS2 CXCL14 
24 CST3 MGP CTSK 49 EMP1 MFAP4 FNDC1 





Group 2 displays an intermediate stage, including many markers of both ASCs and MAFs. 
To find the most unique and representative gene(s) for Group 2, we focused on the top 20 genes 
of its attractor and calculated the ranking increment when compared with the rankings of the same 
genes in the attractors of the other two groups. We considered a ranking increase of greater than 
50 as significant. As a result, we found that RARRES1 is the only gene satisfying the criterion in 
both comparisons.  
Gene RARRES1 (aka TIG1) appears in the beginning of the ASC to MAF transformation 
process and in all samples of Group 2. This is consistent with the known fact that it plays an 
important, though not yet clear, role in regulating proliferation and differentiation of adipose 
tissue-derived mesenchymal stem cells [186]. In contrast, the expression of RARRES1 diminished 
in Group 3, disappearing completely in the final stages of differentiation when COL11A1 is 
expressed strongly (consistent with suggestions that it is a tumor suppressor [187], [188]).  
 
Differential expression analysis on fibroblasts: We also performed DE analysis on the classified 
fibroblasts between the three sample groups defined above (Materials and Methods; see complete 
DE gene lists in Table C.3). Importantly, the results of such analysis represent the full population 
of fibroblasts and not necessarily the expression changes in the particular cells undergoing the 
ASC to MAF transformation.  
For the Group1 to Group 2 stage, genes CFD and DPT were the most downregulated genes, 
consistent with the downregulation of adipose-related genes. On the other hand, the top 
up-regulated gene was phospholipase A2 group IIA (PLA2G2A), whose encoded protein is a 
member of a family of enzymes catalyzing the hydrolysis of phospholipids into free fatty acid. At 
the same time, other extracellular matrix genes are also strongly up-regulated, as expected.  
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For the Group 2 to Group 3 stage, remarkably, PLA2G2A again shows as the top DE gene, 
however this time it is down-regulated. Similarly, the tumor suppressor RARRES1, which was 
significantly up-regulated in the early stage becomes down-regulated in this stage. On the other 
hand, the most significantly up-regulated genes, following the top gene COL11A1, were matrix 
metalloproteinase (MMP11), collagens of type X and XII (COL10A1 and COL12A1), THBS2, 
and growth factor-binding protein 3 (IGFBP3), whereas CFD, APOD, and C7 continued 
decreasing their expression levels. Thus, this stage represents the final formation of 
COL11A1-expressing MAFs.  
The top differentially expressed gene PLA2G2A is not among the top genes of any 
attractors we identified and is expressed by less than half of cells, even in Group 2 in which it 
appears. Therefore, it is expressed by cells in Group 2 that are not among those undergoing the 
ASC to MAF transformation, although it probably still plays an important related role (Discussion) 
and many previous studies referred to its effects on prognosis of multiple cancer types [189]–[191].  
 
5.3.2 Pancreatic ductal adenocarcinoma dataset (trajectory inference)  
We independently applied TI analysis on the PDAC fibroblasts by using the Slingshot [167] 
method, to examine the cell states. We first performed unsupervised clustering on the identified 
fibroblasts (Materials and Methods), resulting in four subgroups X1, X2, X3, and X4 (Figure 
5.1a) with the top differentially expressed genes shown in Figure 5.1b. We discarded one of these 
clusters (X4) from further TI analysis, because it mainly expressed the IL1 CAF marker HAS1 
[189]–[191][192], which is not expressed by either ASCs or MAFs (and does not appear at all in 
Table C.1), and contained only 3% of fibroblasts resulting almost exclusively from patient T11 




Figure 5.1 Overview of PDAC fibroblasts. (a) 6,267 fibroblasts originated from 11 control 
pancreases and 23 tumor samples were partitioned into four groups X1–X4. Fractions of the 
fibroblasts were  45%, 38%, 14%, and 3%. (b) Table showing the top 20 DE genes for each cluster. 
(c) Bar plots presenting the numbers of cells captured for each cluster. 
 
As seen from the list of top DE genes, X1 contains MAF genes top ranked (including 
MMP11, COL11A1, THBS2, and INHBA), X2 has RARRES1 at the top, and X3 has ASC genes 
top ranked, including DPT, C7, CXCL12 and CFD. Consistently, Figures 5.2a and 5.2b show the 
single trajectory path resulting from TI analysis, where X3 is the starting point and X1 is the end 
point of the trajectory, whereas X2 (highly expressing RARRES1), is an intermediate point, 






X1 X2 X3 X4
1 MMP11 RARRES1 PRSS1 HAS1
2 COL11A1 MGP DPT AREG
3 FN1 TIMP1 CLPS HAS2
4 C1QTNF3 COL14A1 CTRB1 NR4A3
5 CTHRC1 C1R PTN IL6
6 COL10A1 CST3 C7 SEMA6A
7 GJB2 C7 ADH1B RP1-3J17.3
8 COL12A1 SOD3 FXYD2 GPRC5A
9 SDC1 MFAP4 PNLIP KLF4
10 POSTN CTSC SEPP1 TFPI2
11 COL1A1 C1S AMY2A NR4A2
12 IGFL2 SERPINF1 FMO2 CREM
13 COL5A2 IGFBP7 INS KDM6B
14 THBS2 C3 CXCL12 PLAUR
15 MMP14 SFRP4 SYCN ADAMTS4
16 INHBA SPARCL1 CFD SAT1
17 COL1A2 TGM2 ALDH1A1 MLLT11
18 GREM1 F2R CPA1 MEDAG
19 PLAU TSHZ2 FBLN5 NFATC2





Figure 5.2 Trajectory analysis of PDAC. (a) Trajectory analysis of 6,075 fibroblasts. Colors-coded 
for pseudotime changes, red presenting the beginning of differentiation and blue presenting the 
end. (b) Color-coded trajectory analysis of fibroblasts for annotated three clusters. (c) GAM fit to 
pseudotime-ordered expression data to visualize the trend of gene expression. (d) Expression of 
adipose-related genes along the ASC-MAF lineage. The x axis shows the cell orders and the y axis 
shows the normalized read count. (e) Expression of MAF genes along the ASC-MAF lineage. (f) 











Table C.4 shows the top 100 genes with zero P value, ranked by their variances, resulting 
from pseudotime-based differential gene expression analysis (Materials and Methods). We can 
clearly identify as top-ranked several ASC genes, as well as MAF genes, whereas some general 
fibroblastic markers, such as DCN, are missing, consistent with the continuity of the  ASC to MAF 
transformation. We then used a GAM fit to pseudotime-ordered expression data to visualize the 
trend of gene expression (Figure 5.2c). 
There was a prominent difference between adipose-related genes and MAF genes. The 
expression of the adipose-related genes steadily fell across the process (Figure 5.2d) whereas the 
expression of MAF genes gradually increased (Figure 5.2e). A significant negative correlation 
emerged between these two groups of genes; for example, COL11A1 (the last among the MAF 
genes to increase its expression) was exclusively overexpressed in the mature MAFs, which did 
not express C7. Of particular interest, genes RARRES1 and SFRP4 (Figure 5.2f) increased 
consistently at the beginning and then decreased after reaching a peak, suggesting they play 
important roles in the differentiation path.  
 
5.3.3 Validation in other cancer types  
Next, we validated the ASC to MAF transformation hypothesis in other solid cancer types. 
Although we could not find currently available datasets as rich as the PDAC dataset, we selected 
those containing a large (at least 100) number of fibroblasts and separately analyzed each of them, 
obtaining consistent results. Specifically, we used four scRNA-seq datasets from HNSCC [169], 
ovarian cancer [170], lung cancer [171] and breast cancer [172]. 
The COL11A1-expressing MAF signature has been confirmed to be a pan-cancer signature 
[161], [193]–[195] (Table 5.1). Therefore, the most important validation task was to confirm the 
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existence of the APOD/CFD/CXCL12/MGP/PTGDS-expressing ASCs as the starting point of the 
transformation, and to also confirm that some samples are at an intermediate stage, expressing 
genes such as RARRES1, SFRP4 and THBS2, in addition to the core ASC genes, demonstrating 
they are at an intermediate stage of the transformation. 
 
Head and neck squamous cell carcinoma: For the HNSCC dataset, the authors of the paper 
presenting the data [169] reported that the cancer-associated fibroblasts in the dataset can be 
partitioned into two subsets, which they named CAF1 and CAF2. In table s5 of that paper, the top 
three differentially expressed genes of the CAF2 group are CFD, APOD, and CXCL12, whereas 
the full gene list for CAF2 presented in the same table s5 also includes genes MGP, C3, C7, DPT, 
and PTGDS. This strongly suggests that the partitioning used in the paper was influenced by the 
presence of an ASC subpopulation, identical, or at least very similar to, those discovered in the 
PDAC. Similarly, the list of differentially expressed genes for CAF1 in table s5 includes genes 
INHBA, THBS2, CTHRC1, POSTN, MMP11, COL5A2, and COL12A1, suggesting that the 
identified CAF1 subpopulation was influenced by the presence of differentiated MAFs that would 
eventually express COL11A1. Finally, gene RARRES1 also appears among the list of CAF2 genes, 
suggesting it was captured among cells that had started the process of ASC to MAF transformation. 
In our independent analysis, we performed clustering, identifying 1,026 fibroblasts from 
all available cells (Figure 5.3a; Materials and Methods). Two fibroblastic clusters (X7 and X9) 
expressed MAF-associated genes (COL11A1, COL12A1, MMP11, INHBA, THBS2, COL10A1, 
COL8A1, and FN1) and ASC-associated genes (APOD, C7, and PTGDS), respectively (Table 





Figure 5.3 Unsupervised clustering of four datasets from HNSCC, ovarian cancer, lung cancer, 
and breast cancer. (a) t-SNE embedding of the whole HNSCC dataset. (b) t-SNE embedding of 
the whole ovarian cancer dataset. (c) t-SNE embedding of the mesenchymal cells from the lung 
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Among the individual patients, we found that the most prominent case was sample 
HNSCC28, which contains a rich set of cells undergoing differentiation. Applying the attractor 
finding algorithm on the fibroblasts of that sample (Table C.6) resulted in genes LUM, APOD, 
COL6A3, PDGFRA, DCN, and CFD being among the top-ranked, revealing that it represents an 
ASC population. Furthermore, the presence of genes THBS2, MFAP5, and VCAN in the same 
attractor revealed that these cells have already started undergoing the transformation.   
 
Ovarian cancer: For the ovarian dataset, the clustering results showed two clusters (X6 and X9) 
expressing MAF-associated genes and ASC-associated genes, respectively (Figure 5.3b, Table 
C.7; Materials and Methods). Among individual patients, we found that those validating our 
hypotheses most are HG2F and LG2, both of whose datasets, consistently, contain cells from the 
fatty omental tissue. Table C.6 includes the corresponding two attractors identified in the cells of 
each patient. Among the top ranked genes for HG2F are DCN, LUM, C1S, C7, and C3, but also 
RARRES1, suggesting they represent fibroblasts undergoing the transformation, whereas the 
LG2-based attractor contains highly ranked all three MAF genes COL11A1, INHBA, and THBS2.  
 
Lung cancer: The dataset contains a large number (> 50,000) of cells, but we only classified ~2% 
(= 1,346) among them as mesenchymal cells, including fibroblasts and pericytes (Materials and 
Methods). Among those cells, there were two fibroblastic clusters (X1 and X2) expressing 
MAF-related genes (COL11A1, COL12A1, MMP11, INHBA, THBS2, COL10A1, COL8A1, and 
FN1) and ASC-related genes (APOD, C7, and PTGDS), respectively (Figure 5.3c, Table C.8). 
The presence of the ASC to MAF transformation is evident by the attractors identified in the 
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mesenchymal cells for patients 4 and 3 (Table C.6). The former prominently contains genes CFD, 
PTGDS and C7, whereas the latter contains THBS2, COL10A1, and INHBA.  
 
Breast cancer: The size of the breast cancer dataset is small (~ 1,500 cells in total), and 169 cells 
among them were classified as mesenchymal (Materials and Methods). By further clustering 
these cells, we identified ASCs (X1) and MAFs (X3; Figure 5.3d, Table C.9). ASC-related genes 
(APOD, MFAP4, and CFD) were identified in X1, whereas MAF-related genes (COL10A1, 
COL11A1, MMP11, INHBA, FN1, THBS2, AEBP1, and COL12A1) are among the top 15 of X3. 
Patients PT089 and PT039 contained the highest proportions (> 50%) of the ASC and MAF 
subpopulations, respectively,  and we found consistent results in their attractors (Table C.6), as the 
former contains C1S, C1R, CXCL12, PTGDS, and C3, while the latter contains THBS2, 
COL11A1, and COL10A1, at top-ranked positions. 
 
5.3 Discussion 
The fact that adipose tissue contributes to the development of cancer as a result of its interaction 
with malignant cells has been recognized in numerous studies [196]–[203] but the underlying 
mechanisms remain unclear. This work sheds light on these mechanisms. Using techniques from 
systems biology, we established a cancer-associated transformation starting from cells belonging 
to a population of adipose-derived stromal cells co-expressing both fibroblastic genes such as 
LUM and DCN, as well as adipose-related genes such as APOD, PTGDS, CFD, and C7. The end 
result of this transformation is another cell population expressing a precise pan-cancer signature 
(shown in Table 5.1) of metastasis-associated COL11A1/INHBA/THBS2-expressing fibroblasts 
(MAFs), which we had identified previously [21], resulting only after malignant cells have 
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encountered adipose tissue. We also provided a detailed description of the gradual modification of 
the gene expression profile, concluding that the cells undergoing this transformation exhibit a 
transient overexpression of some genes, such as RARRES1 and SFRP4. 
This transformation is part of a complex biological process of interaction with the adipose 
tumor microenvironment, and is naturally accompanied by modifications in other cell populations, 
including tumor cells, pericytes, and other types of fibroblasts. For example, tumor cells become 
increasingly invasive in the process, as they undergo epithelial-to-mesenchymal transition. It 
appears that transforming growth factor-beta signaling plays an important role in the 
transformation, as we had speculated by the prominent presence of related genes INHBA and 
THBS2 [21], and as also proposed in various studies [158], [160], [204]. 
This work is closely related to many previous research efforts referring to cell populations 
named “adipose derived mesenchymal stem cells,” “adipose derived fibroblasts (ADFs),” and 
“cancer-associated adipocytes (CAAs).” For example, it has been found that ADFs promote tumor 
progression [205] following further de-differentiation of CAAs [206]. As shown in our results, 
however, the adipose-derived stromal cell population undergoing the transformation to the 
COL11A1-expression cancer-associated fibroblasts is naturally present in normal adipose tissue. 
Furthermore, several previous bioinformatics analyses have identified clusters closely 
resembling the ASC and MAF subpopulations. Notably, the C9 and C10 clusters [195] and the 
CAF2 and CAF1 clusters [169] in recent papers, closely resemble the ASC and MAF profiles. 
Such results validate the accuracy of the current work, which relies on detailed and extensive 
gene-association-based analysis, in addition to clustering and trajectory inference, thereby pointing 
to the precise core of the underlying mechanisms.  
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We also found that PLA2G2A is the single most differentially overexpressed gene in some 
fibroblast population (though not in those undergoing the transformation itself) in the intermediate 
stage of the process, and then it is also the most differentially underexpressed at the final stage. 
This gene is a phospholipase catalyzing the hydrolysis of phospholipids into fatty acids. On the 
other hand, it has been recognized that fatty acid oxidation is associated with the final 
COL11A1-expressing stage of the transformation [207]. These results suggest that lipid metabolic 
reprogramming plays an important role in the metastasis-associated biological mechanism [208]. 
We hope that our results will give rise to testable hypotheses that could eventually lead to 
the development of pan-cancer metastasis-inhibiting therapeutics by targeting potential causal 
biological mechanisms or driver genes identified in this paper, involved in the ASC to MAF 
transformation. For example, although RARRES1 is considered a tumor suppressor [187], [188], 
consistent with its silencing at the final stage, its increased expression is actually associated with 
the initiation of the transformation of ASCs. Similarly, another gene whose expression increases 
at the initial stage is SFRP4, which is a Wnt-pathway regulator whose expression has been found 





Chapter 6: Conclusions and Future Work 
 
6.1 Conclusions 
In this thesis, I described various computational analyses of high-throughput omics data for 
biomedical applications. From DNA sequencing to RNA sequencing, from expression to 
methylation, from bulk tissue to single cell, I demonstrated the unique properties of different 
biomolecular data types and showed that interrogations of them can bring a great amount of 
biological information that underlies diseases. 
 Chapter 2 presents a winning model I developed when participating in a crowd-sourced 
benchmarking DREAM 10 SMC-Het Challenge [35]. This Challenge included three different 
sub-challenges that covered various attributes of the tumor, including its purity, number of 
subclones, subclone genotypes and the phylogenetic relationships among subclones. To accurately 
infer tumor subclonality by answering these sub-challenge questions, I developed a cascade 
ensemble model based on the Dirichlet process mixture model. This model consists of four 
connected modules incorporating extensive use of the genomic attributes of tumors to detect false 
positives of mutation callings and adjusting subclonal predictions using the information of copy 
number aberrations. With gold-standard datasets and robust scoring metrics, this model 
outperformed the benchmark methods and won first place in the leaderboard.   
Chapter 3 shows a meta-analysis of expression and methylation signatures in six different 
neuropsychiatric disorders (including schizophrenia, bipolar disorder, major depression, 
alcoholism, Alzheimer’s, and Parkinson’s). We identified several consensus co-expression and 
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co-methylation signatures using gene expression and DNA methylation data from the postmortem 
prefrontal cortex of patients and healthy controls. Among results, we identified a pair of strongly 
interrelated E–M signatures showing consistent and significant disease association in multiple 
types of disorders. This E–M signature was enriched for interneuron markers, and we further 
demonstrated that it is unlikely for this enrichment to be due to varying subpopulation abundance 
in normal interneurons across samples. Moreover, gene set enrichment analysis revealed 
overrepresentation of stress-related biological processes in this E–M signature. Our integrative 
analysis of expression and methylation profiles, therefore, suggests a stress-related epigenetic 
mechanism in the brain that could be associated with the pathogenesis of multiple neuropsychiatric 
diseases. 
 Chapter 4 introduces 2DImpute, an imputation algorithm specifically developed to identify 
and correct false-zero entries existing in single-cell RNA-sequencing data. It features preventing 
excessive correction by predicting false zeros and imputing their values by making use of the 
interrelationships between both genes and cells in the expression matrix. By applying it to datasets 
from various sequencing protocols, we showed that 2DImpute outperforms several leading 
imputation methods that are constrained by respective drawbacks. This algorithm has been 
implemented in an R package and is freely available at GitHub. 
Chapter 5 describes a recent project aiming to identify the origin of a universal 
metastasis-associated fibroblastic cell population prominently expressing COL11A1, THBS2, and 
INHBA. By performing attractor-based analysis, trajectory inference and unsupervised clustering 
analysis on single cell expression data from many cancer types, we achieved consistent results that 
a cancer-associated transformation of naturally occurring normal adipose-derived stromal cells 
produces these fibroblasts. Focusing on a rich pancreatic cancer dataset, we also provide a detailed 
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description of the continuous modification of the gene expression profile of the fibroblastic 
population as they transition from APOD-expressing adipose-derived stromal cells to 
COL11A1-expressing metastasis-associated fibroblasts, identifying the key genes that participate 
in this transformation. 
 
6.2 Future Work 
With the rapid technological advances in NGS, we are entering the era of single cell 
sequencing. Beyond sequencing the transcriptome of single cells (like the data used for Chapters 
4 and 5), this technology has been extended to the genome [56] and methylome [213]. Furthermore, 
compared to the analyses of single omics data type, analyzing multi-omics from the same single 
cells can provide unambiguous inferences regarding the links between these measurements of 
genotypes and phenotypes, which is even more exciting [214]. For example, we can capture more 
accurate epigenetic signatures which are associated with diseases in specific cell types by 
analyzing the transcriptomics and epigenomics data profiled from same single cells (as we studied 
in Chapter 3); we can confidently classify distinct cell populations from a tumor (as we did in 
Chapter 2) or investigate other relationships between genetic and transcriptional heterogeneity by 
making use of both DNA and RNA sequencing profiles from the same cells, whereas the prevalent 
practices so far remains based on the genetic aberrations inferred from scRNA-seq data [215] due 
to limitations of multi-omics data. Ongoing technological advances [216], [217] will see 
improvements in the single-cell multi-omics approaches, which will boost the generation of 
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Appendix A: Supplementary Materials for Chapter 3 
 
A.1 Supplementary Tables 
Table A.1 Cell type enrichment. P values of the enrichment for different cell type markers, using 
the single cell reference lists from human and mouse brain tissues. OPC stands for 
oligodendrocyte progenitor cell. 
 E1 E2 E3 M3 M4 M5 
Human 
OPC 1 0.66 1 0.15 1 0.86 
Oligodendrocyte 1 1 1 3.10E-08 1 1 
Astrocyte 1 2.20E-13 1 0.06 1 1 
Microglia 1 1 1 1 1 1 
Neurons 0.0033 1 1 1 1 0.0046 
Endothelial 1 1 1 1 1 1 
Mouse 
Ependymal 1 0.94 0.57 1 1 1 
Oligodendrocyte 1 0.85 1 1.40E-23 0.4 1 
Microglia 1 1 0.85 0.82 1 1 
CA1.Pyramidal 0.45 1 0.81 0.31 0.035 2.40E-16 
Interneuron 0.0018 0.94 0.81 0.87 0.059 0.0035 
Endothelial 1 0.57 0.21 0.01 0.96 0.096 
S1.Pyramidal 0.088 1 0.57 0.096 0.51 1.60E-11 
Astrocyte 1 1.40E-16 0.76 0.028 0.51 0.011 





Table A.2 Pairwise correlations between methylation signatures. FDR-adjusted P values by 
Pearson’s correlation test between pairwise methylation signatures in individual datasets. 
 GSE49393 GSE61107 GSE61380 GSE61431 GSE74193 GSE59685 GSE80970 
M1/M2 4.7E-50 5.3E-44 5.2E-29 4.1E-49 6.4E-314 8.4E-131 2.6E-171 
M1/M3 0.93 0.16 0.76 0.68 0.89 0.27 0.27 
M1/M4 0.24 0.073 0.83 0.68 0.8 0.34 0.59 
M1/M5 0.93 0.54 0.39 0.68 0.85 0.48 0.15 
M2/M3 0.93 0.16 0.72 0.68 0.85 0.27 0.27 
M2/M4 0.27 0.13 0.76 0.68 0.76 0.27 0.59 
M2/M5 0.93 0.51 0.39 0.68 0.75 0.44 0.15 
M3/M4 0.045 0.05 0.32 0.68 0.012 0.92 0.015 
M3/M5 2.3E-15 1.3E-19 0.000000011 7.7E-12 2.00E-101 3.3E-35 2.4E-27 
M4/M5 0.0056 0.51 0.85 0.68 0.079 0.27 0.067 
 
 
Table A.3 Pairwise correlation between E-M signatures. FDR-adjusted P values by 
hypergeometric test on the overlapping genes between expression and methylation signatures. 
 M3 M4 M5 
E1 1 1.90E-04 0.1 
E2 0.01 0.1 0.13 
E3 0.62 0.78 0.011 
 
 
Table A.4 Disease association by LME. Two versions of significance of disease association for 
each signature evaluated by the linear mixed-effects regression method are included, of which 
one is “pure” (Model 0, without covariates included) and the other is “confounder-adjusted” 
(Model 1, with covariates included). 
See ‘Data Table S4.xlsx’ in [176]. 
 
 
Table A.5 Full list of E1–M4 signature. Full list of the overlapping genes between E1 and M4 
signatures. The columns represent the gene symbols, the corresponding probes, the scores in the 
two signature gene lists, and the minimum of the two scores. The list is ranked by the minimum 
scores in decreasing order. 




Table A.6 Methylation signature enriched regions. P values evaluated for the enrichment of 
CpG methylation probes located in specific genomic regions for all the consensus co-methylation 
signatures. 
 M1 M2 M3 M4 M5 
Island 1.2E-49 1 1 0 1 
Shore 1 0.76 1 1 4.1E-59 
Shelf 1 1.1E-08 1.5E-22 1 0.000002 
N_Shore 0.98 0.9 1 1 4.7E-25 
N_Shelf 1 0.0014 9.4E-12 1 0.0027 
S_Shore 1 0.35 1 1 3.9E-27 
S_Shelf 1 0.000002 2.6E-11 1 0.0002 
Others 1 1 1 1 1 
Forward 0.56 0.53 0.98 0.2 0.57 
Reverse 0.48 0.51 0.024 0.8 0.45 
Promoter 6.2E-06 7.5E-13 0.19 8E-149 0.69 
 
 
Table A.7 Significance of GO STRESS. Shown are the overlapping genes for each consensus 
signature with two stress-related GO gene lists: GO_CELLULAR_RESPONSE_TO_STRESS and 
GO_REGULATION_OF_RESPONSE_TO_STRESS, and the corresponding P values.   
See ‘Data Table S7.xlsx’ in [176]. 
 
 
A.2 Complementary information for confirming the significant disease associations 
A.2.1 Investigating potential confounding effects from additional covariates. 
 
In the main text, we identified significant and consistent disease associations for co-expression 
signatures E1 and E2 by using linear mixed-effects (LME) model controlling for age, gender and 
postmortem interval. However, in addition to these three covariates, there are additional ones that 
might affect the disease associations we observed. Because the information of these covariates is 
not available in every dataset, we evaluated their associations with the signatures per dataset. We 
reasoned that if the result shows no significance (P > 0.05), we could claim that this covariate does 




Therefore, we analyzed the additional covariates’ associations with E1 and E2 signatures 
in individual datasets by using one-way ANOVA test (for “antipsychotics,” we tested the 
association only on patients), and the resulting P values are listed in the tables. Related information 
was extracted from the original publications of the data sources. 
A. SMRI_AltarC 
 
Covariates Suicide Smoking Alcohol Drugs Antipsychotics 
E1 0.35 0.80 0.13 0.73 0.75 




Covariates Suicide Smoking Alcohol Drugs Antipsychotics 
E1 0.85 0.19 0.25 0.69 0.44 




Manner of death: The control and case samples in this data cohort have a similar cause of 
death, bronchopneumonia being the most common case followed by the carcinoma. 
Substance abuse: Patients had no access to drugs or alcohol of abuse.  
Antipsychotics: Most patients had been treated with neuroleptic drugs when they became 
available, with relatively low doses. Only one patient was neuroleptic naïve at death, and 
four patients took relatively high doses.   
D. GSE21138 
 
Covariates Suicide Antipsychotics 
E1 0.45 0.09 









Covariates Suicide Alcohol Drugs Antipsychotics 
E1 0.75 0.37 0.77 0.18 
E2 0.85 0.78 0.72 0.16 
 
F. GSE20168  
 
No more information is available. 
 
G. GSE54567, GSE54568, GSE54570 
 
Covariate Method of death (natural, accidental, suicide) 
E1 0.30 
E2 0.52 
Antipsychotics: Cases were free of psychotropic medication or illegal drugs, and controls 
were drug-free. 
 
A.2.2 Replicating disease associations by nonparametric test 
In addition to the LME models, we also applied a robust nonparametric approach to obtain 
“baseline” significance of the disease association. It was performed per disease per dataset. The 
results shown below are striking in the sense that significant associations with concordant 
directions occurred repeatedly in different datasets and disorders (from different studies). 
Although we did not involve covariate adjustment here, it is still unlikely to happen if no 
relationship exists between the signatures and the disease diagnoses, which in turn can be used as 
a complementary evidence for the disease associations we identified.   
P values were calculated by performing the Mann–Whitney U test on the diagnosis in each 
individual dataset. For datasets that contained more than one disease type, we tested the association 
for each disease separately. The arrows beside the P values indicate the direction of differential 
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expression in patients: ¯ (­) indicating the down- (up-) regulation of the signature identified in 
patients.  














NS, not significant, for P value ³ 0.05. 
 









NS, not significant, for P value ³ 0.05. 
 
   
Diseases Datasets E1 E2 
Schizophrenia 
SMRI_AltarC NS NS 
SMRI_Bahn 0.040 ¯ 0.012 ­ 
GSE17612 NS NS 
GSE21138 0.024 ¯ 0.016 ­ 
Bipolar disorder 
SMRI_AltarC 1.9×10-4 ¯ NS 
SMRI_Bahn 0.035 ¯ NS 
GSE5388 0.015 ¯ NS 
Parkinson’s GSE20168 0.016 ¯ NS 
Major depression 
SMRI_AltarC 0.016 ¯ NS 
GSE54567 NS NS 
GSE54568 NS NS 
GSE54570 NS NS 
Diseases Datasets E1 E2 
Alzheimer’s GSE36980 0.0040 ¯ NS 
Alcohol use disorder GSE49376 NS  0.036 ­ 
Parkinson’s GSE68719 1.1×10-4 ¯ 0.014 ­ 
Major depression GSE101521 NS NS 
Bipolar disorder BrainGVEX 0.023 ¯ NS 




Appendix B: Supplementary Materials for Chapter 4 
 
B.1 The imputation order of Step 3 and Step 4 in 2DImpute  
To decide the order of two imputation steps (Step 3 and Step 4 in Materials and Methods / 
2DImpute in Chapter 4), we compared the imputation accuracy of using only one of them. We 
used the masked version of the melanoma data [148] in which 2% of non-zero entries had been 
randomly chosen and set to be zero. We first applied Step 1 and Step 2 in the 2DImpute algorithm 
sequentially on the data, identifying suspected dropouts and 12 eligible attractor metagenes (see 
‘Supplementary_Table_S4.xlsx’ in [218]) which involved 757 unique genes.  
 
For comparison, we imputed the dropouts in these genes using methods described in Step 
3 (i.e. linear regression model on co-expressed genes) and Step 4 (i.e. kNN imputation based on 
similar cells), respectively. Then, we calculated the RMSEs between the imputed and the actual 
values for both cases. Results showed that the imputation based on co-expressed genes has higher 
accuracy (RMSE = 0.651) than those based on similar cells (RMSE = 0.714). The above histogram 
of the errors, defined as the difference between imputed values and truth, also shows that more 
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entries are imputed with smaller errors by using the imputation method based on co-expressed 
genes.   
 
B.2 Sensitivity analysis of parameter t  
Different values chosen for parameter t affect the imputed results. With smaller t, more zeros will 
be determined as spurious and hence get imputed; on the other hand, fewer zeros will be imputed 
if a greater t is used. We performed sensitivity analysis for parameter t under different choices (t 
= 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, and 0.7) by using the figures of merit we defined in the section 
of Materials and Methods in Chapter 4. 
We first examined the pairwise Pearson correlation between cells using the 10x scRNA-seq 
dataset [146]. As shown in the following figure, we found that the correlation is quite robust when 
t is no greater than 0.3. However, for larger t choices, the performance falls substantially and 
converges to the results of data without imputation because too few zeros are imputed.   
 
Next, we examined the effect of t by assessing its ability to retain a balanced separation 
between predicted true and false zeros for macrophage-specific marker CD68 in the 
FACS-purified CD45+ dataset [147]. As shown in the violin plots below, the boundary between 
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the two modes become obscure when t < 0.2, indicating that more zeros are incorrectly identified 
as false with a smaller t. 
Thus, combining the two cases discussed above, we choose t = 0.2 as the default parameter. 
In practice, users can adjust the value of t around the default according to their scRNA-seq datasets 
in hand, which are profiled by various platforms. The rule of thumb is that smaller t is used with 
sparser data (i.e., more zeros) and larger t with denser data (i.e. fewer zeros). 
 
 
B.3 More explanation on normalized mutual information   
Mutual information (MI) has been used as a general measure of the correlation between two 
random variables [99]. We used a spline-based estimator [174] to estimate MI values. Let’s denote 
the MI between the continuous expression levels of two genes, G1 and G2, as I(G1, G2). We 
further normalize it by dividing by the maximum of the estimated I(G1, G1) and I(G2, G2), so the 
maximum possible values of I(G1, G2) is 1. More details can be found in the original paper 




B.4 Assumption of linear relationship between genes in the co-expressed attractors  
Assuming a linear relationship is a simplified way to model the relationship between co-expressed 
genes, which we have realized and therefore we choose to use mutual information (contrary to a 
linear association measure such as Pearson correlation) that is able to capture nonlinear 
associations as well when identifying co-expression attractor signatures (Materials and Methods 
in Chapter 4). However, we found that, to predict dropout values, this assumption proves effective 
in general (Figure B.5). Moreover, this assumption is used in other imputation methods that make 
use of the information from gene-to-gene relationships as well. For example, SAVER [131] also 
employs a linear regression model between the most predictive genes and the gene of interest.  
 
B.5 Robustness of 2DImpute to the number of cells  
The proposed algorithm features borrowing information from intrinsic relationships between genes 
and cells. Therefore, larger number of cells will definitely benefit the performance of imputation. 
As the single cell sequencing technologies have been developed, the size of scRNA-seq data 
generated increases exponentially in recent years, which is usually at least in the magnitude of 
hundreds or thousands. In such cases, our algorithm would generally work well because a great 
deal of information accrues from the interrelationships of genes and cells that the algorithm can 
use. However, in some cases where the numbers of cells are relatively very small, such as < 100, 
2DImpute may have deteriorated performance, as will other imputation methods that rely on using 
only the information present in the original data. Hence, as discussed in the review paper for 
imputation methods [135], methods [219] making use of new information from external large 
reference datasets such as the Human Cell Atlas [123] could benefit.  
118 
 
We used the 10x scRNA-seq [146] to demonstrate the effect as follows. We randomly 
selected subsets of cells with different sizes (n = 1,500, 1,000, 500, 100, and 50) to create subset 
expression matrices. For each subset matrix, we applied 2DImpute to impute zeros. Then we 
calculated the mean pairwise Spearman correlations between cells using expression data before 
(unimputed) and after imputation (2DImpute), and the results are shown in the table below. Overall, 
the performance of 2DImpute is quite robust to different cell sizes, evidenced by constantly 
decreasing inter-cell correlations and increasing intra-cell correlations at the same time (Materials 
and Methods in Chapter 4). On the other hand, we observed that the performance became slightly 
worse when the number of cells was close to or smaller than 100.     
Number of cells All (=3388) 1500 1000 500 100 50 
Inter-cell correlation (between two cell types) 
Unimputed 0.30 0.27 0.26 0.23 0.13 0.08 
2DImpute -0.04 -0.06 -0.08 -0.07 0.06 0.04 
Intra-cell correlation for Jurkat cell type 
Unimputed 0.43 0.41 0.40 0.37 0.29 0.23 
2DImpute 0.62 0.62 0.64 0.62 0.57 0.60 
Intra-cell correlation for 293T cell type 
Unimputed 0.39 0.37 0.36 0.33 0.25 0.20 
2DImpute 0.61 0.61 0.61 0.56 0.42 0.48 
 
 
B.6 Supplementary Tables and Figures 
Table B.1 Comparison of pairwise gene-to-gene correlation matrices of recovered values with the 
true correlation matrices, as measured by CMD. 
 2DImpute scImpute SAVER MAGIC DrImpute VIPER 
N = 50 0.09 0.02 0.11 0.14 0.04 0.02 





Figure B.1 Imputation accuracy measured by (a) Root Mean Squared Error (RMSE) and (b) Mean 




Figure B.2 Violin plots showing the distributions of additional cell type marker genes (T cells: 




Figure B.3 Violin plots showing the distribution of genes corresponding to the antibodies used in 
FACS experiments, before and after imputation in two additional FACS-purified scRNA-seq 
datasets: (a) CD8B as a marker of cytotoxic T cells in populations of all T cells and only cytotoxic 
T cells, respectively, in GSE108989 [151] (b) CD3D as marker of T cells in populations of all cells 





Figure B.4 Bar plots showing the mean pairwise cell-to-cell Pearson correlation before and after 
imputation, in which error bars corresponds to one standard deviation; “293T” and “Jurkat” 






Figure B.5 Scatter plots of the top two genes (x-axis and y-axis, respectively) in one of the 
co-expressed signatures identified in each dataset. The blue line represents the regression line 






Appendix C: Supplementary Materials for Chapter 5 
 
C.1 Supplementary Tables 
Table C.1 LUM-seeded attractors (top 100 genes) identified in each PDAC sample.  
See ‘Supplementary Table S1.xlsx’ in [220]. 
 
Table C.2 Top 20 genes ranked by their mutual information with COL11A1 in each of the PDAC 
Group 3 patients.  
See ‘Supplementary Table S2.xlsx’ in [220]. 
 
Table C.3 Differentially expressed genes between fibroblasts from different PDAC sample groups.  
See ‘Supplementary Table S3.xlsx’ in [220]. 
 
Table C.4 Top 100 genes of temporally expressed genes on the pseudotime variable.  
See ‘Supplementary Table S4.xlsx’ in [220]. 
 
Table C.5 Differentially expressed genes among different clusters of the HNSCC dataset.  
See ‘Supplementary Table S5.xlsx’ in [220]. 
 
Table C.6 LUM-seeded attractors (top 100 genes) of validating samples from other cancer types.  




Table C.7 Differentially expressed genes among different clusters of the ovarian cancer dataset.  
See ‘Supplementary Table S7.xlsx’ in [220]. 
 
Table C.8 Differentially expressed genes among different clusters of mesenchymal cells from the 
lung cancer dataset.  
See ‘Supplementary Table S8.xlsx’ in [220]. 
 
Table C.9 Differentially expressed genes among different clusters of stromal cells from the breast 
cancer dataset.  
See ‘Supplementary Table S9.xlsx’ in [220]. 
 
